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Introduction: Chronic graft-versus-host disease (cGVHD) is a serious complication following 
allo-HSCT characterized by immune dysregulation, organ dysfunction, risk for infection, and 
distressing symptoms. Complications may include scleroderma, hepatic dysfunction and 
bronchiolitis obliterans.  Advances in allo-HSCT for many hematologic dyscrasias (e.g. acute 
and chronic leukemias, aplastic anemia, and myelodysplastic syndrome) have improved survival 
which has generated a renewed focus on survivorship issues.  Distressing symptoms are noted as 
negatively impacting quality of life (QoL).  The relationship between inflammation and 
behavioral responses may impact symptom characteristic thus examining patterns and levels of 
inflammation with symptoms is relevant.  Objective: The aims of this study were to examine 1) 
levels of symptoms (cGVHD specific, general symptoms, and cluster symptoms [pain, depression 
and fatigue]), inflammation (cytokines [Interleukin {IL}-1β, IL-6, IL-10, TNF, and INF-γ] and 
C-reactive protein [CRP]) and QoL in patients diagnosed with cGVHD and 2) relationships 
between and among symptoms, inflammation and QoL in individuals with cGVHD.   
Methods: A cross-sectional study design examined 24 individuals (ages 29-79) with cGVHD 
enrolled from an NCI-designated cancer center after obtaining informed consent. Data were 
collected using medical record and validated questionnaires.  Plasma cytokine levels were 
measured using BioRad® multiplex assay. C-reactive protein levels were measures using an 
enzyme-linked immunosorbant assay.  Statistical analyses included descriptive statistics and 
pairwise correlations.  Results: Participants (58.3% female) with cGVHD had multiple, 
concurrent symptoms. Several pro-inflammatory cytokines were higher in participants with 
symptoms versus those without symptoms. IL-6 correlated with lack of energy (r= .42; p= .04) 
and dry mouth (r= .42; p= .04).  IL-10 was correlated with difficulty sleeping (r= .43; p= .03).  
Sexual dysfunction correlated with social well-being (r= -.44; p=.03). Many symptoms 
negatively correlated with QoL.  Conclusion: Findings from this study, one of the first to 
examine levels of symptoms and inflammatory markers in individuals with cGVHD, demonstrate 
significant relationships among symptoms, inflammation, and quality of life.  The relationship of 
inflammatory biomarkers with symptoms and symptom severity emphasize the need for further 
interdisciplinary research.  Further understanding mechanisms associated with symptoms is 













 The focus of inquiry for this dissertation study was prompted by observations made by an 
experienced oncology certified nurse and though an extensive literature review which revealed 
gaps in the literature about cGVHD.  Individuals with many hematologic dyscrasias such as 
acute and chronic leukemias, aplastic anemia, and myelodysplastic syndrome may receive 
hematopoietic stem cell transplantation (bone marrow transplantation) as a life-saving 
intervention.  Receiving stem cells that are not “self” cells is termed an allogeneic donor. A late 
effect complication that is serious and not uncommon after receiving allogeneic donor cells is 
cGVHD.  Though the etiology of cGVHD is poorly defined, it is marked by immune 
dysregulation and inflammatory proliferation.  Bone marrow transplants have increased greatly 
over the past ten years (Hahn, 2013). This increase is due, in part, to new treatments prior to 
transplant that allow patients who once would not be eligible for a transplant to obtain one 
(Hahn, 2013). As a consequence of both the increase in the number of transplants and 
conditioning regimens, the number of individuals diagnosed with cGVHD is increasing.  
Survivorship issues, such as quality of life (QoL), have been gaining attention as the focus of 
research in cGVHD.  Symptoms have been found to influence QoL in cGVHD; however, the 
literature is limited in its description of the number of symptoms, and various characteristics of 
symptoms such as frequency, severity and distress (Lynch-Kelly, 2014).  Symptoms were 
therefore chosen as the focus of this study as a way to gain preliminary insight into QoL of 
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individuals with cGVHD.  This researcher’s philosophical assumptions are consistent with the 
biobehavioral framework which holds that biology and behavior are inextricably linked and 
should be examined concurrently.  As cGVHD is a complication involving an over-exaggerated 
inflammatory response and there is evidence that cytokines (surrogate markers of inflammation) 
play a role in the development and presentation of symptoms, it was logical to examine cytokines 
in relation to symptoms of cGVHD (Ratanatharathorn, Ayash, Lazarus, & Uberti, 2001) .    
Prior to the establishment of the specific aims for this study, an extensive literature 
review was conducted to determine what was known about symptoms, cytokines, and quality of 
life of patients diagnosed with cGVHD.  Findings from the review provided evidence about the 
involvement of symptoms in cGVHD. Symptoms are more pronounced when cGVHD is more 
severe (Fall-Dickson, 2010).  A limitation of the research is that symptoms have been examined 
in relation to the organ affected by cGVHD and usually with a single measure (Lynch-Kelly, 
2014).  There was some consistency regarding which cytokines were examined in cGVHD 
(Lynch-Kelly, 2012).  Individuals with cGVHD were found to have lower QoL than other 
populations (McQuellon et al., 1997).  Also, QoL negatively correlated with cGVHD severity 
(Pidala et al., 2011).  What was not known from the literature was an extensive profile of 
symptoms, if cytokines were related to the symptoms, and how symptoms related to QoL. Thus 
the specific aims for this study were to: 1) examine the levels of symptoms (cGVHD specific, 
general symptoms, and cluster symptoms [pain, depression and fatigue]), inflammation 
(cytokines [Interleukin {IL}-1β, IL-6, IL-10, TNF, and INF-γ] and C-reactive protein [CRP]) 
and QoL in patients diagnosed with cGVHD and 2) examine the relationships between and 
among symptoms, inflammation and QoL in individuals with cGVHD.  Knowledge about 
symptoms and biological mechanisms (e.g. increased systemic inflammation expression) 
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involved in symptom manifestation is important for the development and testing of novel 
interventions to successfully manage symptoms and improve QoL for patients with cGVHD.   
Findings from this study lend evidence about symptoms individuals diagnosed with 
cGVHD may be experiencing. It also provides information about median cytokine and CRP 
levels as well as some comparison cytokine levels between individuals with a certain symptom 
and individuals not experiencing that certain symptom.  A mean QoL score is also provided.  
This study also provides insight into relationships that may exist among and between symptoms, 
inflammation and QoL. In this study, many individuals were experiencing multiple symptoms 
concurrently and had varying levels of frequency, severity, and distress.  There were significant 
relationships among symptoms and cytokines and CRP as well as among symptoms and QoL. 
Information gained from this study serves as a starting point by providing preliminary 
information about symptoms, cytokines and QoL of cGVHD. This information may be used to 
move the science forward in this challenging population and may eventually lead to the 
development and testing of novel interventions to mitigate symptoms thereby increasing the QoL 
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Symptoms, Cytokines, and Quality of Life of Patients with Chronic Graft-Versus-Host Disease: 




Hematopoietic stem cell transplantation has become the standard treatment for many 
hematologic cancers including acute leukemia, chronic myelogenous leukemia, and multiple 
myeloma.  There has been a 165% increase in the number of allogeneic hematopoietic stem cell 
transplants (alloHSCT) from 1994-2005 and survival rates post 100 days transplant have 
increased nearly 86% (Hahn et al., 2013).  Patients receiving an alloHSCT are at risk for 
developing a serious, potentially life-threatening complication known as chronic graft-versus-
host disease (cGVHD).  This is a complex, multisystem issue involving immune dysregulation 
and immunodeficiency, impaired organ function, and decreased survival (Baird and Pavletic, 
2006).  This phenomenon occurs in as many as 90% of all alloHSCT recipients who survive 
greater than 100 days post-transplant (Lee, Cook, Soiffer, & Antin, 2002; Lee, Vogelsang, & 
Flowers, 2003).  Any of the body systems can be affected by cGVHD.  Cutaneous and ocular 
cGVDH occur most often and pulmonary and hepatic cGVHD pose the greatest risk for 
mortality.  In addition to being the most serious complication of alloHSCT, cGVHD is also the 
most common (Pidala et al., 2011; Vogelsang, 2011).  Debilitating consequences of cGVHD 
include loss of sight, pulmonary disease, and joint contractures as well as death due to chronic 
immune suppression secondary to prolonged immunosuppressive therapy (Filipovich et al., 
2005).   
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Understandnig the frequency and severity of symptoms and the interplay between 
symptoms and inflammation, as indicated by levels of cytokines, may be major factors 
contributing to the quality of life of patients with cGVHD.  Patients with cGVHD may 
experience similar symptoms as other cancer survivors such as pain, depressive symptoms, and 
fatigue; however, due to the lack of literature aimed at helping patients with cGVHD manage 
their symptoms, adequate management of symptoms is a barrier to caring for these patients and 
is a major issue (Lee et al., 2002; Perez-Simon, Sanchez-Abarca, Diez-Campelo, Caballero, & 
San Miguel, 2006; Williams et al., 2007). Biological factors such as cytokines are speculated to 
influence the frequency and severity of symptoms that are common among cancer patients and 
are also associated with other autoimmune and chronic conditions similar to cGVHD (Baird & 
Montine, 2008; Bazzichi et al., 2007; Klimiuk et al., 2003; Seruga, Haibo, Bernstein, &Tannock, 
2008). Research in the past has focused on survivorship.  Advances such as earlier 
transplantation, better human leukocyte antigen matching between donor and recipient and 
improvements in transplant conditioning have increased survivorship (Perez-Simon, Sanchez-
Abarca, Diez-Campelo, Caballero, & San Miguel, 2006).   
Due to increased survivorship of patients with cGVHD, improving quality of life is of 
growing importance (Flowers et al., 2008; Lee et al., 2002; Lee et al., 2003).  Quality of life is 
altered due to many factors among which are symptoms (Monga et al., 2007). Among patients 
surviving hematopoietic stem cell transplantation, quality of life returned to pre transplant levels 
within one to two years except for patients experiencing cGVHD (Baker and Fraser, 2008).  The 
National Institutes of Health (NIH) Chronic Graft-Versus-Host Disease Consortium put forth a 
series of papers in which it was concluded the need for the development and validation of 
biomarkers includes examining both biological and behavioral (patient-reported) measures 
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objectively with quality of life as a possible endpoint to measure success of research testing 
novel interventions for supportive care (Filipovich et al., 2005;).  The aims of this integrative 
review are to determine what is known about the symptoms and cytokine patterns and levels of 
patients with cGVHD and to examine the impact of cGVHD on quality of life.  The goal is to 
identify areas for future research leading to the development and testing of interventions to 
mitigate distressing symptoms of patients with cGVHD thereby improving quality of life.   
Symptoms  
 Symptoms are a major source of distress and discomfort for patients with cancer and are 
a major barrier in caring for patients with cGVHD (Lee et al., 2002; Perez-Simon et al., 2006; 
Theobald, Kirsh, Holtsclaw, Donaghy, & Passik, 2003;).  The National Institutes of Health 
(2002) reported that the most commonly experienced symptoms among patients with cancer are 
pain, depression, and fatigue.  Insomnia is also frequently reported as a symptom associated with 
cancer (Fox & Lyon, 2007; Fox, Lyon, & Farce, 2007; Theobald et al., 2003).  In a study 
examining cancer, it was reported that as many as 90% of cancer patients experience pain, 91% 
fatigue, and up to 25% depression (Fox & Lyon, 2006; Fox & Lyon, 2007).  The symptoms 
experienced by patients with cancer may be due to the cancer itself and/or due to the treatments.  
Symptoms, particularly fatigue, may persist well into survivorship (Oh & Seo, 2011).  A major 
role of the oncology nurse is to decrease the burden of symptoms.   
Cytokines  
Biobehavioral science is based in the assumption that the biology of a phenomenon is 
inextricably linked with behavior thereby making it necessary to examine them as two 
dimensions of the same whole.  It is speculated that cytokines act neurologically to induce 
psychological and behavioral changes (Kelley, 2003).  It is also speculated that the production 
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and release of certain cytokines can be effected by the cancer itself and these cytokines may 
mediate symptoms (Seruga, Zhang, Bernstein, & Tannock, 2008).  A call by the National Cancer 
Institute (2006) to investigate strategies for the development and validation of biomarkers in 
cGVHD research could be beneficial in elucidating strategies to combat the devastating effects 
of cGVHD (Baird and Pavletic, 2006).  The establishment of the relationship between symptoms 
and cytokines in this population may serve to determine the interplay of certain inflammatory 
cytokines and symptom severity which may in turn lead to advanced interventions to relieve 
bothersome symptoms for patients with cGVHD.  
There is a growing body of evidence supporting the role of cytokines in symptom 
expression of patients with cancer and other chronic illnesses.  This was first noted as 
observations of a flu-like syndrome of patients treated with immunological agents such as TNF 
and some interleukins (Myers, 2008).  The cytokine interleukin 6 has been linked with the 
symptom of depression and cognitive impairment (Myers, 2008).  Fatigue is the most common 
symptom among cancer patients and may persist well into survivorship.  Interleukin 1 beta and 
Tumor Necrosis Factor have been associated with fatigue (Lee et al., 2004; Seurga et al., 2008). 
Other psychobehavioral symptoms of cancer such as pain and depression have been linked with 
cytokines interleukin 1, interleukin 6, Tumor Necrosis Factor, and interfeuron (Lee at al., 2004; 
Myers, 2008; Seruga et al., 2008).  To develop targeted interventions for symptoms management 
in individuals with cGVHD, it is important to understand the relationship between cytokines and 
symptoms.    
Quality of Life  
 Quality of life is a multi-dimensional concept encompassing several domains including 
physical, emotional, social, and functional (Pidala et al., 2011).  It also includes the subjective 
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measure of an individual’s evaluation of his well-being and functionality (Pidala et al., 2011).  
Quality of life in patients with cancer is altered due to many factors among which one is the 
symptoms that are experienced (Monga et al., 2007).  .  In patients surviving hematopoietic stem 
cell transplantation, quality of life returned to pre transplant levels within one to two years except 
for patients experiencing cGVHD (Baker and Fraser, 2008).  Previous focus on patients with 
hematologic cancers undergoing bone marrow transplant has been survivorship.  With the 
increase in survivorship, focus has turned toward managing the consequences of complications 
such as cGVHD.  Symptom management and quality of life improvement is moving to the 
forefront of cGVHD management (Flowers et al., 2008; Lee et al., 2002; Lee et al., 2003).   
Method 
Articles were retrieved utilizing PubMed, Cumulative Index of Nursing and Allied Health 
Literature (CINAHL), and Cochrane Database of Systematic Reviews databases.  Searches in 
PubMed and CINAHL were conducted to produce an exhaustive list of literature surrounding the 
concepts of symptoms, cytokines and quality of life in conjunction with cGVHD. The full 
description of the search terms used to capture the literature is presented in the appendix.  The 
Cochrane Review Database was searched using the search term “chronic graft-versus-host 
disease”.  Articles were restricted, using search filters, to those adults greater than 18 years of 
age, published in English, and human studies.  Inclusion criteria were: 1) the concept under 
investigation (symptoms, cytokines, or quality of life) must be described in relation to patients 
with cGVHD and must yield specific information about the concept, 2) any research method, and 
3) any research design. 
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Exclusion criteria for this review were: 1) articles that only use broad terms (such as 
“symptoms”) or do not provide any explicit information regarding the concepts under 
investigation (symptoms, cytokines, or quality of life). 
Results 
A total of 704 articles were returned.  The flow diagram (Figure 1) describes the process 
by which articles were selected for this review.  After excluding duplicate articles, applying 
inclusion and exclusion criteria, review of titles, review of abstracts, and finally full text 
screening, 35 articles were used for this literature review.    
Figure 1 








There were a total of 11 symptoms articles included in this analysis.  The literature 
regarding symptoms of patients with cGVDH is varied.  Sample sizes ranged considerably, with 
a sample population as few as n=3 to as many as n=427 (Allen, Greenberg, and Amato, 2009; 
Pidala et al., 2012). One study was conducted at multiple sites (Pidala et al., 2012).  Table 1 
provides a description of the symptom literature.   
Study design.  A variety of descriptive designs were used to examine symptoms in 
cGVHD.  There were no qualitative studies.  There were three case studies (Allen et al., 2009; 
Elad et al., 2003; Takahide et al., 2007), two retrospective studies (Andree et al., 2008; de la 
Parra-Colin et al., 2011) and six prospective, cross-sectional studies (Akpek et al., 2003; Fall-
Dickson et al., 2010; Mitchell et al., 2010; Pidala et al., 2012; Stratton et al., 2007; Treister et al., 
2008).      
Measurement approach.  Researchers relied on a variety of instruments to assess 
patients’ symptoms.  Most (n=6) included information about symptoms that came from provider 
observance or by patient verbal description of symptom presentation (Akpek et al., 2003; Allen 
et al., 2009; de la Parra-Colin et al., 2011; Elad et al., 2003; Stratton et al., 2007; Treister et al., 
2008).  Information provided by patients described the presence of symptoms only.  The visual 
analog scale, used to measure pain severity, was used in three studies (Elad et al., 2003; Fall-
Dickson et al., 2010; Treister et al., 2008).  In studies that examined ocular cGVHD, one used 
the ocular surface index and the other used the Schirmer test to measure symptoms (de la Parra-
Colin et al., 2011; Takahide et al., 2007).  The ocular surface index assesses the presence and 
interference of dry eyes and the Schirmer test assesses the presence of dry eyes.  Two studies did 
not examine site specific cGVHD and used the Lee cGVHD scale (Mitchell et al., 2010; Pidala et 
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al., 2012).  This is a scale that assesses the dimension of symptom bother.  One study did not 
report how symptoms were assessed (Allen et al., 2009).   
Context.  The context in which symptoms were assessed varied.  Some researchers 
assessed symptoms by specific site of disease and some assessed symptoms across sites of 
disease.  Site specific studies include oral (Elad et al., 2003; Fall-Dickson et al., 2010; Treister et 
al., 2008), ocular (de la Parra-Colin et al., 2011; Takahide et al., 2007), gastrointestinal (Akpek 
et al., 2003; Andree et al., 2008),  dermatomysitis (inflammation of the skin and muscles) (Allen 
et al., 2008), and genital, specifically vaginal cGVHD (Stratton et al., 2007). Two studies 
examined symptoms of patients with cGVHD of any site (Mitchell et al., 2010; Pidala et al., 
2012). 
The symptom most frequently examined was pain (Akpek et al., 2003; Elad et al., 2003; 
Fall-Dickson et al., 2010; Stratton et al., 2007; Takahide et al., 2007; Treister et al., 2008).  The 
study conducted by Elad et al. (2003) reported severe oral pain whereas the study conducted by 
Fall-Dickson et al. (2010) reported mild oral pain.  Other symptoms reported in the presence of 
oral cGVHD included odynophagia (pain when swallowing), avoiding certain foods and 
tightness in the mouth (Treister et al. 2008).  Ocular cGVHD studies examined dry eyes, 
photophobia, and foreign body perception (de la Parra-Colin et al., 2011; Takahide et al., 2007). 
The feeling of having a foreign body in the eyes has been described as a “gritty” feeling like sand 
constantly abrading the cornea (Choi, Levine and Ferrara, 2010; Joseph, Couriel, and 
Komanduri, 2008; Vogelsang, 1996).  Both studies that examining ocular cGVHD reported 
patients complained of photophobia (de la Parra-Colin et al., 2011; Takahide et al., 2007).  
Gastrointestinal cGVHD examined nausea, dysphagia, feeling full, heartburn, diarrhea and 
weight loss (Akpek et al., 2003; Andree et al., 2008). Abdominal pain was the most commonly 
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reported symptom in one study (Akpek et al., 2003) and nausea in another (Andree et al., 2008).  
The case study reported by Allen et al. (2009) found muscle weakness (fatigue) and myalgia to 
be the patients’ complaints.  Painful intercourse and pain due to strictures were present in all 
patients (n=33) with vaginal cGVHD (Stratton et al., 2007).  Symptom bother was assessed in 
the two studies that examined symptoms in any site (Mitchell et al., 2010; Pidala et al; 2012).  
The scores were 28.4 and 20.7 respectively, out of a possible 100, with a higher score indicating 
greater symptom bother (Mitchell et al., 2010; Pidala et al., 2012).     Specific symptoms were 
not reported in either of these studies.   
Cytokines 
Cytokines are small proteins that act to regulate the intensity and duration of immune 
response and mediate cell-to-cell communication. Elevated levels of cytokines are associated 
with autoimmune or chronic inflammatory diseases that are comparable to cGVHD (Baird & 
Montine, 2008; Bazzichi et al., 2007; Klimiuk et al., 2003).  A total of 14 cytokine articles were 
included in this analysis. Sample sized ranged from n=3 to n=229 and from a one group design 
to a three group design (Cullup et al., 2003; Kaminska, et al., 2007).  Table 2 provides a 
description of cytokine literature examined in the presence of cGVHD.   
Study design. All reviews articles selected used a descriptive design to examine levels of 
cytokines; however, there was variability in the number of groups and the temporality among 
studies.  Four studies used a single group (Craciun et al., 2002; D’Elios et al., 1997; Gorgun, 
Miller, & Foss, 2002; Poloni et al., 2011).  One study included a donor group (Cullup, Dickson, 
Cavet, Jackson, & Middleton, 2003).  All other studies used two groups (case group and control 
group) (Aractingi, Gluckman, Le Goue, Dubertret, & Carosella, 1996; Bladon & Taylor, 2006; 
Darvay, Salooja, & Russell, 2004; Fall-Dickson et al., 2010; Hettinga, Verdonck, Fijnheer, 
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Rijkers, & Rothova, 2007; Kaminska et al., 2010; Nakamura et al., 2005; Ricci et al., 2006; 
Tauchmanova et al., 2004).  There were two case studies used in this analysis (Hettinga et al., 
2007; Kaminska et al., 2010).  Eight studies were longitudinal (Bladon & Taylor, 2006; Craciun 
et al., 2002; Darvay et al., 2004; Gorgun et al., 2002; Nakamura et al., 2005; Poloni et al., 2011; 
Ricci et al., 2006; Tauchmanova et al., 2004).  Four studies were cross-sectional (Aractingi, et 
al., 1996; Cullup et al., 2003; D’Elios et al., 1997; Fall-Dickson et al., 2010).  .   
Measurement methodology.  Cytokines can be measured through many vectors and by a 
variety of instruments.  There was heterogeneity in methods used by the researchers across 
studies.  The most common (n=10) vector for assessing cytokines was blood (Bladon & Taylor, 
2006; Craciun et al., 2002; Cullup, 2003; D’Elios et al., 1997; Darvay et al., 2004; Gorgun et al., 
2002; Nakamura et al., 2005; Poloni et al., 2011; Ricci et al., 2006; Tauchmanova et al., 2004). 
Other vectors included tissue (n=4), saliva (n=1), and ocular fluid (n=1) (Aractingi et al., 1996; 
D’Elios et al., 1997; Fall-Dickson et al., 2010; Hettinga et al., 2007, Kaminska et al., 2010; 
Poloni et al., 2011).  The method for assessing the measurement of cytokines was inconsistent 
across studies.  The two most often used were flow cytometry and enzyme-linked 
immunosorbent assay.  Flow cytometry was used for cytokine analysis in six studies (Bladon & 
Taylor, 2006; Darvay et al., 2004; Gorgun et al., 2002; Hettinga et al., 2007; Ricci et al., 2006; 
Tauchmanova et al., 2004).  Enzyme-linked immunosorbent assay was used for cytokine analysis 
in three studies (D’Elios et al., 1997; Fall-Dickson et al., 2010; Nakamura et al., 2005).  
Context.  The circumstances in which cytokines were measured include inteventional and non-
interventional studies, site specific and non-site specific studies, and all families of cytokines.  
Interventional studies explored cytokine levels of patients before and after receiving 
extracorporeal photopheresis (Aractingi et al., 1996; Bladon & Taylor, 2006; Craciun et al., 
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2002; Darvay et al., 2004; Gorgun et al., 2002).  Pre-treatment levels of cytokines are reported to 
ascertain presence and levels of cytokines found in patients with cGVHD unmitigated by the 
effects of treatment.  Other studies did not include an intervention. There were both site specific 
and non-site specific articles reviewed.  Site specific articles included cutaneous (n=1), oral 
cGVHD (n=1), ocular (n=1) and renal (Aractingi et al., 1996; Fall-Dickson et al., 2010; Hettinga 
et al., 2007; Kaminska. et al, 2010). The remainder of the reviewed studies are not site specific. 
There are three families of cytokines, hematopoietins (interleukins), interfeurons, and 
tumor necrosis factors.  All studies measured levels of interleukines (IL).  The IL most often 
examined (n=7) was IL-10 (Craciun et al., 2002; Gorgun et al., 2002; Hettinga et al., 2007; 
Kaminska. et al, 2010; Nakamura et al., 2005; Ricci et al., 2006; Tauchmanova et al., 2004). 
Interfeuron gamma was the only interfeuron examined and was the cytokine most often 
measured (n=9) (D’Elios et al., 1997; Darvay et al., 2004; Gorgun et al., 2002; Hettinga et al., 
2007; Kaminska et al., 2010; Nakamura et al., 2005; Poloni et al., 2011; Ricci et al., 2006; 
Tauchmanova et al., 2004).  Tumor necrosis factor was examined in seven studies (Aractingi et 
al., 1996; Bladon & Taylor, 2006; Craciun et al., 2002; Kaminska. et al, 2010; Nakamura et al., 
2005; Ricci et al., 2006; Tauchmanova et al., 2004).  The least examined cytokine was IL-12 
(Poloni et al., 2011).    
Numerous cytokines were measured across studies.  There were consistencies across 
studies with regard to levels of some cytokines while levels of other cytokines across studies 
yielded varied results.  Six studies examined cytokines from the IL-1 family.  Three examined 
IL-1 alpha (α) (Bladon & Taylor, 2006; Cullup et al., 2003; Fall-Dickson et al, 2010) and three 
examined IL-1 beta (β) (Bladon & Taylor, 2006; Craciun et al., 2002; Poloni et al., 2011).  
Among patients with cGVHD, levels of IL-1α and IL-1β were higher in patients with cGVHD 
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across studies than in patients without cGVHD.  There were four studies that assessed cytokine 
IL-2 (Darvay et al., 2004; Kaminska et al., 2010; Ricci et al., 2006; Tauchmanova et al., 2004).  
Results were inconsistent across studies.  Two studies demonstrated elevated levels in patient 
with cGVHD, one demonstrated lower levels of IL-2 among patients with cGVHD and one 
demonstrated no difference between patients with and without cGVHD.  There was 
inconsistency among studies (n=6) that measured levels of IL-4.  Four found there to be no 
difference between patients with and without cGVHD and two found levels of IL-4 to be 
elevated among patients with cGVHD when compared to patients without cGVHD (D’Elios et 
al., 1997; Darvay et al., 2004; Gorgun et al., 2002; Nakamura et al., 2005; Ricci et al., 2006; 
Tauchmanova et al., 2004). Two articles examined IL-5.  One article described no difference in 
IL-5 levels between patients with and without cGVHD and one article described elevated levels 
of IL-5 in patients with cGVHD compared with patients that were not diagnosed with cGVHD 
(Ricci et al., 2006; Tauchmanova et al., 2004). Studies examining IL-6 (n=4) found patients with 
cGVHD to have higher levels of IL-6 than patients without cGVHD (Bladon and Taylor, 2006; 
Fall-Dickson et al., 2010; Hettinga et al., 2007; Kaminska et al., 2010).  In the study conducted 
by Aractingi et al. (1996), there was no difference in the expression of IL-8 between patients 
with cGVHD and patients without cGVHD.  Bladon and Taylor (2006) and Poloni et al. (2011) 
found elevated levels of IL-8 among patients with cGVHD when compared with patients 
withoug cGVHD.  Studies examining IL-10 yield varying results.  Five of the seven studies 
yielded elevated evels of IL-10 (Craciun et al., 2002; Gorgun et al., 2002; Hettinga et al., 2007; 
Kaminskaet al., 2010; Tauchmanova et al., 2004).  The remaining two found no difference in 
circulating levels of IL-10 between patients with and without cGVHD (Nakamura et al., 2005; 
Ricci et al., 2006).  
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Studies examining TNF-α (n=7) and IFN-ƴ (n=9 ) also yielded varying results. Three 
studies examining TNFα found elevated levels between patients with cGVHD and patients 
without cGVHD (Bladon & Taylor, 2006; Kaminska et al., 2010; Tauchmanova et al., 2004). 
Three found no difference in levels of TNFα between patients with cGVHD and patients without 
cGVHD.  Aractingi et al. (1996) reports TNF α is expressed in patients with cGVHD.   
The majority (n=6) of studies examining  IFNʎ in patients with cGVHD report elevated 
levels among patients with cGVHD (Darvay et al., 2004; Gorgun et al., 2002; Kaminska et al., 
2010; Poloni et al., 2011; Ricci et al., 2006; Tauchmanova et al., 2004). Hettinga et al. (2007) 
and Nakamura et al. (2005) report no difference between cGVHD cases and non cGVHD 
controls.  D’Elois et al. (1997) reports IFNʎ is expressed in patients with cGVHD.   
Quality of Life 
A total of 10 quality of life articles were included in this analysis.  Sample size ranged 
from n=37 to n=427 (Kim et al., 2010; Pidala et al., 2011).  Table 3 provides a description of 
quality of life literature examined in the presence of cGVHD.   
 Study design.  All quality of life research articles examined for this review used a 
descriptive study design. Aspects such as the use of a control group and sample size were varied.  
The majority of studies (n=6) used a cross-sectional study design to evaluate the effect of 
cGVHD on QoL (Fall-Dickson et al., 2010; Harris et al., 2010; Imanguli et al., 2010., Pallua et 
al., 2010; Pidala et al., 2011a; Pidala et al., 2011c).  The remainder of the studies used a 
longitudinal study design (Herzberg et al., 2010; Kim et al., 2010; Lee et al., 2006; Pidala et al., 
2011b).  Two studies included a control group (Herzberg et al., 2010; Pallua et al., 2010). The 
remainder of the literature reviewed had a one group design.  Eight studies used standardized 
scores to indicate level of quality of life and Two studies used “population norms” for 
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comparison of quality of life scores (Fall-Dickson et al., 2010; Pidalla et al., 2011b).  Five 
studies included a sample size over one hundred (Herzberg et al., 2010; Imanguli et al., 2010; 
Pidala et al.,2011; Pidala et al., 2011; Pidala et al., 2012).   
Measurement methodology.  The tools to capture quality of life of patients with 
cGVHD are well documented in the literature as being reliable and valid instruments.  The 
functional assessment of cancer therapy general was used in three studies (Fall-Dickson et al., 
2010; Harris et al., 2010; Imanguli et al., 2010).  The same measure with an the addition of a 
bone marrow transplant subscale was used in five studies (Herzberg et al., 2010; Lee et al., 2006; 
Pidala et al., 2011a; Pidala et al., 2011b; Pidala et al., 2011c).  Pidala et al. (2011a,b,c) and Kim 
et al. (2010)  used the short form- 36 to assess quality of life in addition to the functional 
assessment of cancer therapy.  The human activity profile scale was also used in the study by 
Pidala et al. (2011c).   
Context.  Quality of life in patients with cGVHD is explored in site specific populations 
and non-specific site populations and there are a variety of factors associated with quality of life. 
Eight of the ten studies included all patients with cGVHD and did not examine specific sites 
(Harris et al., 2010; Herzberg et al., 2010; Kim et al., 2010; Lee et al., 2006; Pallua et al., 2010; 
Pidala et al., 2011a; Pidala et al., 2011b; Pidala et al., 2011c). Two studies evaluated quality of 
life of patients with oral cGVHD (Fall-Dickson et al., 2010; Imanguli et al., 2010).  Factors 
associated with quality of life include severity of cGVHD (Fall-Dickson et al., 2010, Paulla et 
al., 2010), spirituality (Harris et al., 2010), physical functioning (Herzberg et al., 2010), and 
salivary gland dysfunction (Imanguli et al., 2010).  Having cGVHD showed to decrease quality 
of life across studies.  The study by Pidala et al. (2011c) did not find a difference in quality of 




This review sought to examine the current literature to find out what is known about 
symptoms, cytokines and quality of life of patients with cGVHD.  The goal is to identify areas 
for future research leading to the development and testing of interventions to mitigate distressing 
symptoms of patients with cGVHD thereby improving quality of life. A total of 36 articles were 
extracted and reviewed.  Each variable was examinied for information regarding study design, 
measurement and methodology, and context.  All of the literature reviewed used a descriptive 
study design.  The methods for measuring the concepts are varied as are the results. Thus it is 
difficult to draw conclusions.  There is evidence that patients with cGVHD are experiencing 
distressing symptoms and cytokine dysregulation.  Quality of life appears to be affected by many 
factors associated with cGVHD.      
Symptoms  
Symptoms are a departure from normal function or feeling noticed by an individual and 
may be indicative of presence of disease or abnormality and are a major source of distress and 
discomfort for patients with cancer (Theobald, Kirsh, Holtsclaw, Donaghy, & Passik, 2003).  
The National Institutes of Health (2002) reported that the most commonly experienced 
symptoms among patients with cancer are pain, depression, and fatigue.  Insomnia is also 
frequently reported as a symptom associated with cancer (Fox & Lyon, 2007; Fox, Lyon, & 
Farce, 2007; Theobald et al., 2003).  In a study examining cancer, it was reported that as many as 
90% of cancer patients experience pain, 91% fatigue, and up to 25% depression (Fox & Lyon, 
2006; Fox & Lyon, 2007).  The symptoms experienced by patients with cancer may be due to the 
cancer itself and/or due to the treatments.  Symptoms, particularly fatigue, may persist well into 
survivorship (Oh & Seo, 2011).  A major role of the oncology nurse is to decrease the burden of 
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symptoms.  Patients with cGVHD may experience similar symptoms; however due to the lack of 
literature aimed at helping patients with cGVHD manage their symptoms, adequate management 
of symptoms is a major barrier to caring for these patients (Williams et al., 2007).  The literature 
is lacking in symptom management and little is known about which symptoms patients 
experience and to what extent. Distressing symptoms are the primary reason people seek medical 
attention, yet for patients with cGVHD, the symptoms experienced are not well elucidated.  Most 
articles examined for this review imply symptoms are a source of distress; however, few sought 
to present a symptom profile using a multi-symptom measure that quantifies symptom 
frequency, severity, and interference with daily life. The literature examined for this review 
regarding the symptom experience is limited.  Few studies examined symptoms of cGVHD using 
validated measures.   
Another gap in the literature regarding symptoms in the presence of cGVHD is there are 
many systems affected by cGVHD that were not identified.  There were no reviewed published 
studies that examined symptoms for pulmonary or hepatic involvement.  Other sites affected by 
cGVHD, such as the skin, which is the most commonly affected organ, were lacking in the 
literature. Implementing studies to include larger sample size with the use of validated measures 
would add to the existing body of knowledge about which symptoms patients with cGVHD are 
experiencing and the frequency, severity and distress of symptoms for better symptom 
management.  
Cytokines  
Biobehavioral science is based in the assumption that the biology of a phenomenon is 
inextricably linked with behavior thereby making it necessary to examine them as two 
dimensions of the same whole.  It is speculated that cytokines act neurologically to induce 
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psychological and behavioral changes (Kelley, 2003).  It is also speculated that the production 
and release of certain cytokines can be effected by the cancer itself and these cytokines may 
mediate symptoms (Seruga, Zhang, Bernstein, & Tannock, 2008).  A call by the National Cancer 
Institute (2006) to investigate strategies for the development and validation of biomarkers in 
cGVHD research could be beneficial in elucidating strategies to combat the devastating effects 
of cGVHD (Baird and Pavletic, 2006).  The establishment of the relationship between symptoms 
and cytokines in this population may serve to determine the interplay of certain inflammatory 
cytokines and symptom severity which may in turn lead to advanced interventions to relieve 
bothersome symptoms for patients with cGVHD.  
The complexity in the micro-environment of cGVHD is evident in the literature.  There 
are numerous speculations as to the role that cytokines play in the presentation of this 
complication of allogeneic hematopoietic stem cell transplantation.  Continued research is 
necessary to draw conclusion about the levels and patterns of cytokines present in patients with 
cGVHD and to establish relationship between cytokine levels and the occurrence and severity of 
cGVHD.  Future research examining cytokines is essential for better understanding the 
relationship of cytokine-mediated immune dysfunction and the development of cGVHD in 
patients receiving an allogeneic hematopoietic stem cell transplant.  Also, inflammatory markers 
associated with symptom presentation are necessary to gain understanding of the interplay of the 
biology and behavioral responses of patients with cGVHD.   
Quality of Life  
 Quality of life in patients with cancer is altered due to many factors among which one is 
the symptoms that are experienced (Monga et al., 2007).  Previous focus on patients with 
hematologic cancers undergoing bone marrow transplant has been survivorship.  With the 
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increase in survivorship, focus has turned toward managing the consequences of complications 
such as cGVHD.  Symptom management and quality of life improvement is moving to the 
forefront of cGVHD management (Flowers et al., 2008; Lee et al., 2002; Lee et al., 2003).   
Quality of life is a major concern for patients with cGVHD.  Symptoms that cause 
patients distress may be a contributing factor that impacts overall perception of quality of life; 
however, there is a gap in the literature to substantiate this hypothesis.  One study examined in 
this review sought to elucidate the impact  symptoms have on quality of life for patients with 
cGVHD and this study is site-specific.  The majority of articles examining quality of life for this 
review used a cross-sectional design and did not include  healthy controls.  Many of the patient 
samples in the quality of life literature are over 100 participants and  describe patient 
characteristics; however, there is a lack of description as to cGVHD classification in accordance 
with NIH guidelines.  There is a gap in the literature of sample homogeneity as to which 
characteristics of cGVHD were examined in relation to quality of life thus definitive associations 
between cGVHD and quality of life are not established. 
Conclusion 
It does appear from the literature reviewed that patients with cGVHD are experiencing a 
myriad of distressing symptoms.  The establishment of the impact that distressing symptoms 
have on patients’ quality of life has yet to be well characterized.  The literature also provides 
evidence that inflammatory markers may indicate the severity and possibly the persistence of 
cGVHD.  Correlative studies have demonstrated an association among symptoms, cytokines and 
quality of life and have also demonstrated length of time since diagnosis and the severity of 
cGVHD also effect patient perception of quality of life.    An initial step to the development and 
research of novel interventions to ameliorate distressing symptoms and increasing quality of life 
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for patients with cGVHD is to examine and describe, in depth and breadth, the symptoms 
patients are experiencing and how these symptoms are related to biological mechanisms such as 
inflammatory cytokines.  Also, how these factors together influence the quality of life for 
patients with cGVHD.  There is a need for further research examining these aspects of cGVHD 
using reliable and valid instruments as well as instruments that are comparable to draw 
conclusion across studies.  This would allow the science for the development of interventions to 
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Symptoms, Cytokines and Quality of Life of Patients with Chronic Graft-versus-Host Disease 
following Allogeneic Hematopoietic Stem Cell Transplantation:  
A Cross-sectional, Correlational Study 
 
 
Chronic graft-versus-host disease (cGVHD) is a serious complication following 
allogeneic hematopoietic stem cell transplantation (HSCT) marked by immune dysregulation and 
debilitating clinical sequelae (Perez-Simon, Sanchez-Abarca, Diez-Campelo, Caballero, & San 
Miguel, 2006).  Allogeneic transplant refers to HSCT using donor stem cells versus autologous 
HSCT which is the use of previously harvested stem cells from the patient who then receives his 
own cells back during the transplant.  Donor cells for allogeneic HSCT are matched according to 
human leukocyte antigens (HLA), proteins that make up a person’s tissue type and play an 
important role in immune response (National Cancer Institute).  As cGVHD is a complication of 
donor immune cells’ ability to assimilate in the host environment, donor cells mount an over-
exaggerated immune response (Bishop & Pavletic, 2008; Choi, Levine, & Ferrara, 2010). This is 
called an allo-reaction and is characterized by inflammatory responses that may have deleterious 
effects; therefore examining patterns and levels of inflammation are of importance (Vose, 2011). 
Manifestations of cGVHD usually appear several months after transplantation and the 
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pathophysiology of cGVHD remains vexing (Ratanatharathorn, Ayash, Lazarus, Fu, & Uberti, 
2001).   
Reports have demonstrated that as many as 80% of patients undergoing allogeneic HSCT 
develop cGVHD (Lee, Cook, Soiffer, & Antin, 2002; Lee, Vogelsang, & Flowers, 2003).  
Complications include scleroderma, destruction of saliva and tear ducts, and liver and pulmonary 
dysfunction (Filipovich et al., 2005).  With an increase in number of allogeneic transplants and a 
decrease in mortality due to earlier transplantation, better HLA matching between donor and 
recipient and improvements in transplant conditioning, there is a resultant shift of focus to 
survivorship issues (Flowers et al., 2008). Important survivorship issues include symptom 
management, enhancing quality of life (QoL) and improving functional status for survivors of 
allogeneic HSCT (Flowers et al., 2008; Lee et al., 2002; Lee et al., 2003; Schlomchik, Lee, 
Couriel, & Pavletic, 2007).  Progress toward achieving these outcomes includes adequate 
assessment and targeted therapeutic interventions to mitigate distressing symptoms and long-
term complications (Perez-Simon et al., 2006).   
Symptom management is a major issue for patients experiencing cGVHD (Lee et al, 
2002; Perez-Simon et al., 2006).  Yet, there remains a gap in the literature establishing the 
relationship between symptoms in this population and QoL (Lynch-Kelly, 2014).  Further, there 
has been little study of the relationship of symptoms and biological markers of cGVHD although 
the interplay between biological markers and symptoms may impact the frequency and severity 
of symptoms experienced by patients with cGVHD (Lynch-Kelly, 2014).   
Understanding symptoms of cGVHD, inclusive of the biological underpinnings of 
symptoms, is a fundamental step toward managing symptoms effectively.  Knowing the 
relationships among symptoms and QoL gives insight into the impact symptoms may have on 
73 
 
QoL for patients with cGVHD.  Thus, the aims of this study were to 1) examine the levels of 
symptoms (cGVHD specific, general symptoms, and cluster symptoms [pain, depression and 
fatigue]), inflammation (cytokines [Interleukin {IL}-1β, IL-6, IL-10, TNF, and INF-γ] and C-
reactive protein [CRP]) and QoL in patients diagnosed with cGVHD and 2) examine the 
relationships between and among symptoms, inflammation and QoL in individuals with cGVHD.  
Knowledge about symptoms and biological mechanisms (e.g. increased systemic inflammation 
expression) involved in symptom manifestation is important for the development and testing of 
novel interventions to successfully manage symptoms and improve QoL for patients with 
cGVHD.   
Background and Significance 
HSCT has become the standard treatment for many hematologic cancers including acute 
leukemias, chronic leukemias, multiple myeloma, and myelodysplastic syndrome (Pidala, 2011).  
Before HSCT, patients receive conditioning therapy of chemotherapy, radiation, or both to 
destroy the cancer cells after which donor cells are infused through a central venous catheter 
similarly to a blood transfusion (Alyea et al., 2006; Gupta, Lazarus, & Keating, 2003; Toze et al., 
2005).  There has been a 165% increase in the number of allogeneic HSCT from 1994-2005 and 
survival rates post 100 days HSCT increased nearly 86% (Hahn et al., 2013).  This increase in 
HSCT is partially due to advances in conditioning known as a mini transplant involving lower 
doses of chemotherapy and radiation thus allowing HSCT for individuals who may have once 
been ineligible (Hahn et al., 2013). 
One of the complications of HSCT is GVHD.  There are two types of GVHD, acute and 
chronic.  Acute GVHD usually appears within the first 100 days post-transplant and involves 
different immune cell subsets and different cytokine profiles than cGVHD (Ratanatharathorn et 
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al., 2001).  Acute GVHD is speculated to involve alloreactive memory T cells existent in donor 
cells.  Usually, cGVHD presents post 100 days and the pathobiology cGVHD is not well 
elucidated (Pidala, 2011).  The focus of this study is on cGVHD. 
The exact cause of cGVHD is unknown; but is speculated to involve mechanisms 
associated with proliferation and exaggeration of inflammation as with other autoimmune 
disorders (Baird & Montaine, 2008; Bazzichi et al., 2008; Klimiuk, Sierakowski, Domyslawska, 
& Chweicko, 2011).  Diagnosis and staging of cGVHD is relatively recent.  In 2005, the 
National Institutes of Health (NIH) cGVHD consortium developed criteria for distinguishing 
cGVHD by type of onset, severity of presentation, and number of organs involved (Filipovich et 
al., 2005).  Acute GVHD is a primary risk factor for the development of cGVHD.  Other factors 
such as gender match, transplant conditioning, and diagnosis have been identified as risk factors 
of cGVHD as well (Flowers et al., 2011; Remberger et al., 2002).  Any of the body systems can 
be affected by cGVHD.  Skin (cutaneous) and eye (ocular) cGVDH are the most frequently 
occurring while those with lung (pulmonary) and/or liver (hepatic) cGVHD have the highest 
mortality (Pidala et al., 2012; Vogelsang, 2001).  In addition to being perhaps the most serious 
complication following allogeneic HSCT, cGVHD is also the most common (Pidala et al., 2011; 
Vogelsang, 2001).   
Due to increased survivorship of patients with cGVHD, improving QoL is of growing 
importance (Flowers et al., 2011; Lee et al., 2002; Lee et al., 2003).  From December, 2005 
through May, 2006, the National Cancer Institute (NCI) published a series of papers in the areas 
of diagnosing and staging, histopathology, strategies for the development and validation of 
biomarkers, response criteria, ancillary therapy and supportive care, and the design of clinical 
trials for cGVDH (Baird & Pavletic, 2006).  The validation of biomarkers includes examining 
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both biological and behavioral (patient-reported) measures with QoL as a possible endpoint to 
measure success of research testing novel interventions for supportive care (Filipovich et al., 
2005).   
Theory 
            This study adapted the Theory of Unpleasant Symptoms (TOUS) (Lenz, Suppe, Gift, 
Pugh, & Milligan, 1995) to provide the theoretical perspective to explore the relationships 
among symptoms commonly associated with cancer (pain, depression, and fatigue) and QoL in 
patients diagnosed with cGVHD.  The TOUS was developed after observation of symptoms in 
various clinical settings demonstrated there were certain commonalities among symptoms while 
simultaneously exhibiting uniqueness (Lenz et al., 1995).  Symptoms are a multidimensional 
concept including: 1)temporality, 2) quality, 3) intensity, and 4) distress (Lenz et al., 1995). 
Further research led to the conclusion that symptoms rarely occur in isolation but usually more 
than one at a time and that the relationships among the influencing factors, the symptoms 
experienced and the outcome are not linear but interactive (Lenz, Pugh, Milligan, Gift, & Suppe, 
1997).  The TOUS has been used as the framework for many studies in the examination of 
symptoms across many patient populations including cancer symptom research (Chen & Tseng, 
2007; Farrell & Savage, 2010; Fox & Lyon, 2007; Fox, Lyon, & Farace, 2007; Jurgens et al., 
2009).   
The TOUS was modified (Figure 1) to portray the biobehavioral perspective used to 
examine the specific aims of this study.  Biobehavioral research assumes that biology and 
behavior are inextricably linked, thus necessitates examining biological correlates with 
behavioral manifestations.  The model depicts the relationships among concepts examined in this 
study.  It assumes: 1) multiple symptoms occur simultaneously, 2) relationships exist between 
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and among symptoms, 3) inflammation is present and is related to symptoms, and 4) relationship 
exist among symptoms, inflammation, and QoL.  
Symptoms  
Symptoms are a major source of distress and discomfort for patients with cancer (Lee et 
al., 2002; Perez-Simon et al., 2006; Theobald, Kirsh, Holtsclaw, Donaghy, & Passik, 2006).  
Patients with cGVHD may experience multiple symptoms but little is known about which 
symptoms and to what extent, as such adequate management of symptoms is a major barrier to 
caring for these patients (Williams et al., 2007).   
cGVHD specific symptoms.  Symptoms of cGVHD have been predominantly explored 
in studies focusing on a single organ system affected by cGVHD such as skin, mouth, or eyes 
with symptom description related to the specific body system (Lynch-Kelly, 2014). For example, 
studies examining oral cGVHD have focused on dry mouth and oral pain (de la Parra-Colin, et 
al., 2011; Fall-Dickson, 2010; Hettinga, Verdonck, Fijnheer, Rijkers, & Rothova, 2007).  Studies 
examining gastro-intestinal cGVHD, have focused on distressing symptoms of bloating and 
nausea (Akpek et al., 2003).  As cGVHD can affect multiple body systems concurrently, having 
a detailed description of symptoms by body system is important for supportive treatment.  
Findings from cGVHD studies have noted symptoms similar to those of other cancers and 
include pain, nausea, bloating, weight loss, depressive symptoms, and sexual dysfunction (Akpek 
et al., 2003; Andree, 2008; Mitchell et al., 2010; Stratton et al., 2007; Wong et al., 2013). 
General symptoms.  Patients with cancer report the presence of many symptoms such as 
pain, numbness in hands and feet, bowel disturbances, and vomiting (American Cancer Societym 
n.d.).  Insomnia is also frequently reported as a symptom associated with cancer (Fox & Lyon, 
2007; Fox et al., 2007; Theobald et al., 2006). These symptoms may be due to the cancer itself or 
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treatments and have been shown to persist after treatment cessation.  The percentage of 
uncontrolled chronic cancer pain has been shown to exceed 75% in some instances and is 
reported to be a major cause of distress (Caraceni et al., 2001; Stenseth, Bjornnes, Kaasa, & 
Klepstad, 2007).  Approximately 30% of cancer patients report depression (Oh & Seo, 2011).  
Depression may persist well into survivorship and is a predictor of both fatigue and mortality 
(Kroenke et al., 2010; Oh & Seo, 2011).   
Cluster symptoms.  Common symptoms across cancer populations reported by the 
National Institute of Nursing Research (NINR) (2011) are pain, depression, and fatigue.  In a 
studies examining lung, breast and ovarian cancer, it was reported that as many as 90% of cancer 
patients experience pain, 91% fatigue, and up to 25% depression (Chen & Tseng, 2007; Fox & 
Lyon, 2007).  The symptom triad of pain, depression and fatigue often co-occur in patients with 
cancer and are also described in the cGVHD literature but not as concurrent, correlating 
symptoms examined with in-depth measures of pain, depression and fatigue.  Management of 
symptoms requires adequate symptom assessment and is essential for improving QoL (Ross & 
Alexander, 2001).  
Pain.  Pain is the unpleasant sensory or emotional sensation causing distress and is the 
number one reason why people seek medical attention (Cheng, Foster, & Huang, 2003).  Patients 
with cancer may not only be experiencing pain directly related to the cancer process but may 
experience pain caused by treatments.  Pain can cause both physical and psychological suffering 
(Kreitler & Merimski, 2007; Miaskowski et al., 2006).  It has been estimated that 40% to 80% of 
cancer patients experience pain (Porteny & Lesage, 1999).  In order to develop interventions to 
adequately manage pain in this patient population, there must be an adequate assessment of the 
pain (Theobald et al., 2006). 
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Depression. Depression is feeling “sad” or “blue” for an extended period of time and 
these feelings interfere with normal activities (National Institute of Mental Health [NIMH], 
2010).  Symptoms may include feeling sad or empty, hopeless, helpless.  One may have a 
gloomy outlook on life and the inability to feel happiness towards things which used to be 
enjoyable (NIMH, 2010).  Depression and illness often co-exist; one may be the cause, 
consequence or predisposition of the other (NIMH, 2010).  In a study with 215 randomly 
assigned patients with cancer, 68% had a depressed or anxious mood (Massie, 2004).  
Depression is reported as one of the most common symptoms in all types of cancer and 
negatively impacts QoL (Fox et al., 2007; Miaskowski et al., 2004).   
Fatigue. Fatigue is weariness or tiredness or lack of energy (Mendoza et al., 1999).  
Fatigue experienced by the general population serves as a protective response to physical and 
psychological stress and is often relieved by rest. However, for patients with cancer, fatigue is 
described as distressing, life altering, unrelieved by rest, and chronic (Servaes, Verhagen, & 
Bleijenberg, 2002).  Fatigue is the most commonly reported symptom in patients with cancer. It 
is also highly reported by patients after bone marrow transplantation.  Fatigue is thought to be a 
side effect of treatment modalities and a consequence of biologic effects (Lawrence, Kupelnick, 
Miller, Devine, & Lau, 2004; Seyidova-Khoshknabi, Davis, & Walsh, 2011).   Fatigue has been 
described as the symptom that most interferes with daily life.  It has been reported by patients as 
a symptom that begins before diagnosis and persists after treatment completion (Lawrence et al., 
2004; Lyon & Fox, 2007; Fox et al., 2007; Mendoza et al., 1999; Prue, Rankin, Allen, Gracey, & 






Cytokines and CRP.  Cytokines are non-antibody proteins that act as mediators among 
cells to induce or prohibit inflammatory responses in the body.  It is speculated that cytokines act 
neurologically to induce psychological and behavioral changes (Kelley, 2003).  It is also 
speculated that the production and release of certain cytokines can be effected by the cancer 
itself and these cytokines may mediate symptoms (Seruga, Zhang, Bernstein, & Tannock, 2008).  
A call by the NCI (2006) to investigate strategies for the development and validation of 
biomarkers in cGVHD research could be beneficial in elucidating strategies to combat the 
devastating effects of cGVHD (Baird & Pavletic, 2006).  The establishment of the relationship 
between symptoms and cytokines may serve to determine the interplay of certain inflammatory 
cytokines and symptom severity which may in turn lead to advanced interventions to relieve 
bothersome symptoms for patients with cGVHD.  
An acute phase reactant, CRP, was once thought to be produced only by hepatic cells 
(Yeh, 2005).  Studies have now demonstrated both epithelial cells and respiratory cells produce 
CRP.  Furthermore, CRP has a direct effect on epithelial cells to stimulate production of 
cytokines (Gould & Wiser, 2001; Jabs et al., 2004).   Levels of CRP rise in response to 
inflammation and are used in current practice to monitor progression or remission of certain 
conditions and treatment efficacy for some auto-immune conditions such as rheumatoid arthritis 
and systemic lupus erythematous.  These conditions appear to have similar clinical presentations 
as cGVHD (Baird & Montine, 2008; Bazzichi et al., 2007; Klimiuk et al., 2003; Seruga, Zhang, 






The World Health Organization (WHO) broadly defines QoL as the perception an 
individual has of their life situation with regards to goals, expectations, standards and concerns 
(1997).  QoL is affected by many aspects of an individual’s health and encompasses many 
domains such as physical, social, emotional and functional well-being (Cella et al., 1997).  The 
presence of distressing symptoms is one factor that contributes to decreased QoL among cancer 
survivors (Monga et al., 2007).  The evaluation of treatment efficacy once focused on survival 
time (quantity) with little regard for QoL. Currently, one of the considerations for treatment 
efficacy is the impact treatment will have on QoL.  Preservation of as high a QoL as possible is 
now evaluated as a part of treatment decisions.   
Materials and Methods 
Design, Sample, and Setting 
 This study used a prospective, descriptive, cross-sectional design.  Participants were 
recruited from a convenience sample of patients diagnosed with cGVHD receiving post 
allogeneic HSCT care at an urban health care facility. Patients were eligible for participation if 
they were at least 18 years of age, had a diagnosis of cGVHD, and could speak English.  Patients 
were ineligible for participation if they had begun taking antidepressants within a month, were 
pregnant, or incarcerated.  Prior to the conduct of the study, a power analysis calculated using 
nQueary Advisor ® v.7.0 determined that a 0.05 two-sided Fisher’s z test of the null hypothesis 
that the Pearson correlation coefficient p=0, has 80% power to detect a ρ as small as 0.43 when 
the sample size is 40.  However due to recruitment issues, a sample of N=24 was recruited for 





 This study was approved by the Massey Cancer Center’s Protocol Review Monitoring 
Committee and the health care system’s Institutional Review Board.  Patients were referred to 
the study by the transplant center’s medical director in consultation with the attending physician 
and the clinical coordinators.  Written consent was obtained from all participants.  Individual and 
disease factors were collected from both the medical record and self-report by participants.  
Severity of cGVHD was obtained using standard criteria based on evaluation of organ systems in 
accordance with the NIH global rating scale (Filipovich et al., 2005).  Symptom and QOL data 
were collected by patient self-report.  A blood draw for measures of inflammatory cytokines and 
CRP was collected by the clinic nurse via venipuncture or a venous access device at a regularly 
scheduled clinic visit. Study visits took approximately one hour to complete.  Participants 
received a $25.00 visa card after completing the study. 
Measures 
Individual and disease factors.  All individual factors and disease factors were collected 
by either chart review or patient report.  Information collected included demographic information 
on age, race, ethnicity, and marital status.  Other individual factors collected included type of 
cancer, donor characteristics and functional status were also collected.  Disease factors were 
related to cGVHD onset, NIH global rating, blood platelet count and immunosuppressive 
therapy. 
Symptoms. 
cGVHD Specific Symptoms. 
 Lee cGVHD Symptom Scale.  The Lee cGVHD Symptom Scale was used to assess 
symptom bother by body system (Lee et al., 2006).  There are seven subscales, each based on the 
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body system that may be affected by cGVHD: 1) skin, 2) eye and mouth, 3) breathing, 4) eating 
and digestion, 5) muscles and joints, 6) energy, and 7) mental and emotional.  Items are rated 
using a 5-point Likert-type scale where 0 indicates “Not at all” and 4 indicates “Extremely” 
bothered over the past month.  A summary score is created by linearly transforming the mean of 
all items to a 0-100 scale. This measures has demonstrated adequate internal consistency 
reliability with Cronbach’s alphas ranging from .79 to .90 and good convergent validity (Lee et 
al, 2006). The Cronbach’s alpha for this study was .79. 
 General Symptoms. 
Memorial Symptom Assessment Scale.  The Memorial Symptom Assessment Scale 
(MSAS) was used to assess dimensions of 32 prevalent cancer symptoms (Portenoy et al., 1994).  
The MSAS consists of three subscales: 1) physical, 2) psychological, and 3) global distress. Each 
item is assessed for the presence or absence of a particular symptom.  If the symptom is present, 
most items (24) are rated on a 4-point or 5-point Likert-type scale for: 1) frequency (where 1 
indicates “rarely” and 4 indicates “almost constant”), 2) severity (where 1 indicates “slight” and 
4 indicates “very severe”) and 3) distress (where 0 indicates “not at all” and 4 indicates “very 
much”) over the past week.  The distress of a symptom is broadly defined as the extent to which 
a symptom impedes the ability to cope and how much the symptom is a bother (Cleeland, 2000; 
Lenz et al., 1995).  Distress negatively impacts daily living and decreases QoL in patients with 
cancer (Cleeland, 2000). The remaining 8 items are rated on severity and distress only, not on 
frequency.  A mean score is calculated for each item, each subscale, and the total measure. This 
instrument has been tested and validated in many patient populations (Chang, Hwang, Feuerman, 
Kasimis, & Thaler, 2000; Portenoy et al., 1994; Tranmer et al., 2003).  This measure has 
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demonstrated adequate internal consistency reliability with Cronbach’s alphas ranging from .76 
to .88 (Chang et al., 2000; Portenoy et al., 1994). The Cronbach’s alpha for this study was .89. 
Cluster symptoms. 
Pain.  The Brief Pain Inventory (BPI) was used to assess dimensions of pain (Cleeland, 
2009).  The BPI consists of two subscales: 1) severity and 2) interference (Cleeland, 2009). Four 
items assess pain severity and seven items assess interference.  Each item is rated on an 11-point 
Likert-type scale where 0 indicates “no pain” or “no interference” and 10 indicates “the worst 
pain imaginable” or “complete interference” over the past twenty-four hours.  A mean score is 
calculated for each subscale and the total measure.  Fifty percent of the questions must be 
answered to calculate a score. The measure has demonstrated adequate internal consistency 
reliability with Cronbach’s alphas ranging from .80 to .87 for pain severity items and from .89 to 
0.92 for interference items (Cleeland, 2009).  The Cronbach’s alpha for this study was .95. 
Depression.  The depression subscale of the Hospital Anxiety and Depression Scale 
(HADS) was used to assess symptoms of depression (Zigmond & Snaith, 1983). This instrument 
has been used widely in cancer settings as well as general medical settings (Mitchell, Meader, & 
Symonds, 2010).  The depression subscale is comprised of seven items.  Each item is rated on a 
4-point Likert-type scale where 0 indicates “least severe” and 3 indicates “most severe” for how 
the participant is currently feeling.  The score is the sum of all items for the subscale.  The 
measure has demonstrated adequate internal consistency reliability with Cronbach’s alphas 
ranging from .82 to .90 (Mykletun, Stordal, & Dahl, 2001).  The Cronbach’s alpha for this study 
was .77. 
Fatigue.  The Brief Fatigue Inventory (BFI) was used to assess dimensions of fatigue 
(Mendoza et al., 1999). The BFI consists of two subscales: 1) severity and 2) interference.  Three 
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items assess fatigue severity and six items assess fatigue interference.  Each item is rated on an 
11-point Likert-type scale where 0 indicates “no fatigue” or “no interference” and 10 indicates 
“worst fatigue imaginable” or “complete interference” over the past twenty-four hours.  A mean 
score is calculated for each subscale and the total measure (Mendoza et al., 1999; Seyidova-
Khoshknabi et al., 2011).  The measure has demonstrated adequate internal consistence 
reliability with Cronbach's alphas ranging from .95 to .96 (Mendoza et al., 1999, Mendoza, 
Mayne, Rublee, & Cleeland, 2006). The Cronbach’s alpha for this study was .93. 
 Inflammation.   Blood was collected in a 3ml Ethylenediamineteraacidic tube and 
transported (on ice) to the research lab.  The blood was centrifuged at 1030 rpm for 10 minutes at 
4°c.  Plasma was aliquotted to 3 microfuge tubes (500µl each).  Samples were stored in a -80°c 
freezer until processed for analysis.   
 Cytokines.  Serum cytokine levels were analyzed using the BioPlex®(Bio-Rad) 
multiplex assay.  Bioplex allows the simultaneous measurement of multiple cytokines in a single 
biological sample.  Dual laser technology allows for the detection of multiple analytes across 
numerous fluorescent spectra; this provides accurate quantification of cytokines.   
CRP.  Serum CRP levels were measured using the ALPCO’s (American Laboratory 
Products Company) high-sensitivity CRP enzyme-linked immunosorbant assay per 
manufacturer’s protocol.   
QoL.  QoL was assessed using the Functional Assessment of Cancer Treatment- Bone 
Marrow Transplantation (FACT-BMT) (McQuellon et al., 1997).  The FACT-BMT measures 
multiple dimensions of QoL.  It consists of the 27-item FACT –General (G) and a 12-item BMT 
subscale.  The FACT-G assesses physical well-being (PWB) (7-items), social/family well-being 
(SWB) (6-items), emotional well-being (EWB) (6-items), and functional well-being (FWB) (7-
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items).  The trial outcome index (TOI) is the sum of the PWB, FWB, and BMT subscales.  Each 
item is rated on a 5-point Likert-type scale where 0 represents the statement has been “not at all” 
true for the individual and a 4 represents the statement has been “very much” true for the 
individual over the past week (Lau et al., 2002).  To produce the subscale score, the sum of the 
item scores are multiplied by the number of items in the subscale then divided by the number of 
items answered.  At least 50% of the items must be answered to score this measure.  The total 
FACT-BMT score is the sum of all subscores.  The measure has demonstrated adequate internal 
consistency reliability with Cronbach’s alphas of .84 for physical well-being, .69 for 
social/family well-being, .67 for emotional well-being, and .78 for functional well-being.  The 
Cronbach’s alpha was .88 for the FACT-G total and .89 for the FACT-BMT (Kopp et al., 2000; 
Lau et al., 2002).  The Cronbach’s alpha for this study was .91. 
Data Analysis 
 Descriptive statistics were used to characterize the individual and disease factors of the 
sample and to profile symptoms, cytokines and QoL.  Frequencies and percentages were used to 
describe categorical variables.  Means and standard deviations or median and ranges were used 
to describe continuous variables.  Student’s t-tests were performed to compare cytokine and CRP 
levels for each item on the MSAS between individuals who reported having the symptom and 
individuals who did not report having the symptom.  Biologic variables were log transformed to 
meet the statistical assumption of normality.  Specificity was evaluated by visually inspecting the 
dot plot for spectral overlap of biological data.  To test associations among symptoms, cytokines, 
CRP, and QoL, Pearson product-moment correlation coefficient was used for all pairwise 
combinations of variables displaying normal distribution.  Spearman’s rank correlation 
coefficient was used to test associations for skewed data.  All statistics were calculated using 
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statistical software package JMP 10.0.  This was an exploratory analysis thus alpha was set at 
.05.   
Results 
Profiles of Symptoms, Cytokines and QoL 
 The first aim of this study was to examine the levels of symptoms (cGVHD specific, 
general symptoms, and cluster symptoms [pain, depression and fatigue]), inflammation  
(cytokines [Interleukin {IL}-1β, IL-6, IL-10, TNF, and INF-γ] and C-reactive protein [CRP]) 
and QoL in patients diagnosed with cGVHD.  Individual and disease factors are profiled in 
Tables 1 and 2.  In this sample (N=24), the majority of participants were female (58.3%), 
Caucasian (87.5%), and married (79.2%). Half of the participants were not employed. The 
median age of participants was 54 years and ranged from 28 to 73 years.  The median time from 
transplant to cGVHD diagnosis was 191 days with a range of 123 to 702 days.  The mean 
hemoglobin level was 12.5 (2.2).  Most participants (29.2%) had a diagnosis of acute 
myelogenous leukemia.  Most received stem cells from a relative (79.2%) and were gender 
matched (58.8%).  Functional impairment was noted in 91.7% of participants. 
Symptoms. 
 cGVHD specific symptoms.  The Lee scale assessed the bother of a symptom for the past 
week.  For the skin, the most frequently reported symptom was changes in skin color (50%).  On 
the eyes and mouth subscale, dry eyes was the most reported symptom (83%).  Nearly half of 
participants (49%) were either “quite a bit” or “extremely bothered” by dry eyes and 75% were 
bothered by having to use eye drops frequently.  On the breathing subscale, shortness of breath 
was reported by 50% of participants.  Two participants reported being “extremely” bothered by 
the need to use supplemental oxygen.  On the eating and digestion subscale, all participants were 
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able to receive nutrition without any intravenous or feeding tube supplementation. On the 
muscles and joints subscale, being bothered by limited joint movement and “aches” was reported 
by 50% of participants.  On the energy subscale, loss of energy was reported by 79% of 
participants and the need to sleep more was bothersome for 66.7% of participants.  On the mental 
and emotional subscale, difficulty sleeping was the most reported symptoms (58.4%).  The 
symptoms for the Lee cGVHD Scales are reported in Table 3 and Table 4.     
General symptoms.  The MSAS assessed the frequency, severity, and distress of 
symptoms for the past week.  The most frequently reported symptom was lack of energy (83.3%) 
followed by dry mouth (66.7%). Among those experiencing the symptom, the most often 
reported symptoms were dry mouth, and lack of appetite.  The most severe symptoms were pain 
and sexual dysfunction and the most distressing symptoms were sexual dysfunction and lack of 
energy.  The mean scores for each subscale and overall score and description individual 
symptom items of the MSAS are reported in Table 4 and Table 5. 
Cluster symptoms.  Pain, depressive symptoms, and fatigue were examined using in-
depth measures for each symptom.  The majority of participants (54%) reported having pain and 
nearly half (46%) reported interference with activity because of pain.  Pain severity scores for 
worst pain ranged from 1.0 to 10.0, for least pain 0.0 to 4.0, for average from 0.0 to 5.0.  The 
overall median pain severity scores ranged from 0.0 to 5.8.  Pain interference scores ranged from 
0.0 to 8.8.  The overall total pain scores ranged from 0.0 to 6.4.  Nearly all (96%) participants 
reported having some depressive symptoms.  Median scores for depressive symptoms ranged 
from 0.0 to 11.0.  Fatigue severity scores for worst fatigue ranged from 0.0 to 10.0 and for usual 
fatigue ranged from 0.0 to 8.0.  Fatigue interference scores ranged from 0.0 to 9.0. The overall 
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total fatigue scores ranged from 0.0 to 8.0 (see Table 6 for description of cluster symptom 
scores).     
Inflammation.  Blood samples were collected on all participants and the specificity was 
confirmed by visually inspecting the dot plot for spectral overlap of biological data.  In a 
comparison between the serum levels of cytokines, CRP, and general symptoms, there were 
significant differences noted between cytokines and symptoms. Participants reporting lack of 
energy had significantly elevated (difference of 2.23, SE= .98, 95% CI = .19-4.27) serum levels 
of IL-6 compared to individuals who did not report lack of energy (df= 22, t= 2.07, p= .03).  
Participants reporting problems with urination had significantly higher (difference of 1.81, SE= 
.73, 95% CI= .30-3.31) serum levels of IL-1β compared to individuals who did not report 
problems with urination (df= 22, t= 2.07, p= .02).  Participants reporting swelling of arms and 
legs had significantly lower (difference of 1.18, SE= .54, 95% CI= .06-2.3) of serum IL-10 
compared to individuals who did not report swelling of arms and legs (df=22, t= 2.07, p=.04).  
Figures 4a-f present levels of inflammatory markers of patients with and without symptoms 
reported on the MSAS.  Levels of serum cytokines and CRP are reported in Table 7. 
QoL.  The FACT-BMT scores (see Table 8) demonstrate impaired QoL for many 
participants.  The FWB subscale had the lowest mean of all scales measured by the FACT-BMT 
followed by the PWB subscale.  The TOI subscale score was about 72% of the total physical and 
functional well-being.  The ranges for all scales were varied with some participants experiencing 
decreased QoL on all scales.   
Associations among Symptoms, Cytokines and QoL 
 The second aim of this study was to examine the relationships between and among 
symptoms (top three general symptoms and cluster symptoms), inflammation and QoL in 
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individuals with cGVHD.  There were six symptoms identified by the MSAS that were present in 
over 30% of participants with a total mean score greater than 2 out of 4:1) pain, 2) lack of 
energy, 3) dry mouth, 4) difficulty sleeping, 5) shortness of breath, and 6) sexual dysfunction.  
Significant correlations were noted among MSAS items pain, lack of energy, dry mouth and 
sexual dysfunction. The MSAS pain item significantly correlated with the BPI total pain score 
(r= .78; p< .01).  The MSAS lack of energy item significantly correlated with other MSAS items 
dry mouth (r= .48; p= .02) and sexual dysfunction (r= .53; p< .01). The MSAS lack of energy 
item also showed significant correlations with cluster symptoms HADS-D (r= .65; p< .01), and 
the BFI total fatigue score (r= .78; p< .01).  The MSAS sexual dysfunction item significantly 
correlated with the BFI severity subscale (r=.43, p=.03). 
 Dimensions of cluster symptoms demonstrated some significant correlations among each 
other. The BPI total score did not show significant correlations with the BFI total score.  Figure 2 
displays the correlations between the BPI and the BFI. The HADS_D demonstrated significant 
positive correlations with the BPI Interference subscale and all scales of the BFI shown in Figure 
3. 
 Inflammation.  Cytokines and CPR were found to have several significant correlations 
among each other, symptoms, and QoL.  Cytokine IL-1β had significant positive correlations 
with TNF (r= .78; p< .01), IFN-ƴ (r= .97; p< .001), IL-6 (r= .44; p= .031), and IL-10 (r= .79; p< 
.001).  Cytokine IL-6 showed significant correlations with IFN-ƴ (r= .58; p< .01), MSAS item 
lack of energy (r= .42; p= .04), MSAS item dry mouth (r= .42; p= .04), and near significance 
with the EWB subscale (r= -.40; p=.05).  Cytokine IL-10 showed significant positive correlations 
with IFN-ƴ (r= .78; p< .01), TNF (r= .82; p= <.01), and MSAS item difficulty sleeping (r= .43; 
p= .03). TNF was significantly correlated with IFN-ƴ (r= .73; p=< .01).  CRP was significantly 
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correlated with the SWB subscale (r= -.56; p< .01), and was nearing significance with MSAS 
item sexual dysfunction (r= .41; p= .05).  
QoL.  Many significant correlations were found among QoL and pain, depression and 
fatigue.  The MSAS pain item significantly correlated with the PWB subscale (r= -.57, p< .01).  
The MSAS item lack of energy showed significant correlations with the PWB subscale (r= -.70, 
p< .01), the FWB subscale (r= -.53; p< .01), the BMT subscale (r= -.71; p< .01), the FACT-G 
subscale (r= -.64; p< .01), and the FACT_BMT (r= -.68, P< .01).  The MSAS dry mouth item 
correlated to the BMT subscale (r= -.55, p< .01), the TOI subscale (r= -.41; p=.04), and the 
FACT-BMT (r= -.42, p= .04). The MSAS sexual dysfunction item correlated with the SWB 
subscale (r= -.44; p=.03) and the BMT subscale (r= -.44; p= .03).  Cluster symptoms pain, 
depression, and fatigue showed significant correlations with the FACT-BMT and the subscales 
of the FACT-G, TOI, and BMTS.  Correlations among cluster symptoms and QoL are noted in 
Table 9. 
Discussion 
This study described symptoms, inflammation, and QoL and examined associations 
among these variables in a sample of patients diagnosed with cGVHD following allogeneic 
HSCT.  Markers of inflammation (cytokines IL-1β, IL-6, IL-10, TNF, and IFN-ƴ and CRP) have 
been noted in cGVHD literature and were selected to examine as biological correlates of cGVHD 
symptoms (Lynch-Kelly, 2012).  
Reported symptoms and findings of existent relationships from this study highlight the 
symptom complexity of patients with cGVHD.  Among the most pronounced symptoms captured 
by the MSAS were dry mouth, difficulty sleeping, shortness of breath, and sexual dysfunction.   
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Dry mouth was reported among participants with and without oral cGVHD.  Certain 
medications and treatments can cause dry mouth.  Dry mouth can cause serious health issues 
such as an increased number of dental carries and creates an environment for invasion of 
opportunistic microorganisms (Visvanathon & Nix, 2010).  There was a positive association 
between dry mouth and inflammatory marker IL-6 which has been associated with Sjogren’s 
syndrome, a complication of inflammatory cell infiltration of the lacrimal and salivary ducts 
manifesting as dryness of the eyes and mouth (Ratanatharathorn et al., 2001).  Secondary 
Sjogren’s syndrome may be a clinical sequela of cGVHD (Kawanami et al., 2012).  This 
association supports findings by Fall-Dickson et al. (2010) as the potential for IL-6 as a 
candidate biomarker for oral cGVHD.  The significant correlation between dry mouth and lack 
of energy as well as a negative trend between dry mouth and QoL warrant further exploration of 
these findings.     
Sleeping difficulties have been cited as being among the most commonly experienced 
symptoms of patients with cancer and other chronic diseases and has a negative impact on 
physical functioning and poorer QoL (Basta, Chrousos, Velo-Bueno, & Vgontzas, 2007).  A 
positive association between difficulty sleeping and IL-10 is consistent with literature which 
suggestive of dysregulation in the circadian release of IL-10 (Basta et al., 2007; Roque, Correia-
Neves, Mesquita, Palha, & Sousa, 2009).  
 Shortness of breath was reported among all participants with pulmonary cGVHD 
regardless of cGVHD severity. Pulmonary cGVHD carries a higher rate of mortality than 
cGVHD of other body systems (Gazourian et al., 2014).  Careful attention to the respiratory 
status, including assessment of shortness of breath, of patients is essential for early detection of 
pulmonary complications.  Shortness of breath (dyspnea) occurring at rest is a late sign of 
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pulmonary complications so assessment of early signs of dyspnea is important.  Dyspnea is 
subjective and is based on the individual’s perception of feeling short of breath with varying 
degrees of activity.  The Borg dyspnea scale is a widely used scale to assess perception of 
dyspnea (Borg, 1970).  There are objective measures of lung function such as pulmonary 
function tests (PFT).  Patients with cGVHD have PFTs performed at intervals post allogeneic 
HSCT; however, keeping a watchful eye between PFTs and monitoring respiratory status are 
necessary for early intervention.	Strategies to alert providers to a decline in pulmonary function 
earlier than conventional practice could lead to earlier interventions that may result in sustaining 
acceptable pulmonary function (Stadler et al., 2009).  
Sexual dysfunction among individuals with cGVHD is focused on women with vaginal 
cGVHD.  There have been advancements in treatments and strategies to mitigate this symptom; 
however, it still remains an issue.  In a study of 23 women diagnosed with genital cGVHD, 21 
women were unable to remain sexually active due to complications such as pain, scaring and 
strictures (Stratton et al., 2007).  This study demonstrated that sexual dysfunction was not limited 
to only women diagnosed with vaginal cGVHD.  Seven females and four males reported having 
sexual dysfunction.  Two had a diagnosis of vaginal cGVHD, thus this appears to be an issue to 
assess with all individuals with cGVHD (Wong et al., 2013). Sexual dysfunction had significant 
positive correlations with lack of energy, nearing significant positive correlation with 
inflammatory marker CRP, and a significant negative correlation with the SWB QoL subscale.  
Other than fatigue, sexual dysfunction was the only variable to significantly correlate with SWB. 
Pain, depression, and fatigue are established in the literature as being among the most 
common symptoms of patients with cancer.  Significant positive correlations were demonstrated 
among many dimensions of the cluster symptom measures.  Although cGVHD is a complication 
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following treatment, this finding suggests a constellation of symptoms that may form a symptom 
cluster in this population.  Each of the measures used in this study to explore symptoms included 
items for pain, depression and fatigue.  Significant correlations were noted between similar 
items.  Pain, depressive symptoms and fatigue all negatively correlated with QoL.  Exploring 
these relationships over time with a larger sample is necessary for determination.  The positive 
correlations among symptoms and cytokines IL-6, IL-10, and CRP merit examining these 
findings in a larger sample. A significant increase in serum IL-6 levels between patients with and 
without lack of energy was found; however, there was no difference noted in IL-6 levels of 
patients with mild, moderate, or severe cGVHD.  A study conducted by Rohleder, Aringer, and 
Boenter (2012) found increased IL-6 levels in individuals with impaired sleep and fatigue.  This 
finding brings into question the identification of IL-6 as a potential biological correlate of fatigue 
independent of cGVHD severity.  
Cytokines play a major role in influencing and regulating inflammatory responses.  
Dysregulation of cytokines has been associated with auto-immune diseases such as rheumatoid 
arthritis and systemic lupus erythematosus (Kishimoto, 2010; Munroe et al., 2014).  Significant 
correlations were found among cytokines IL-1β, IL-6, IL-10, and IFN-y.  Historically, cytokines 
have been described as pro-inflammatory or anti-inflammatory and instrumental in promoting 
acute responses from T-helper (TH) 1 cells or mediating B-cell proliferation from TH2 cells 
(Mossmann, Cherwinski, Bond, Giedlin, & Coffman, 1986).  TH lymphocytes are demarcated by 
the expression of cell surface molecule CD4 and are identified by the cytokines they produce.  
The discovery of the TH1 and TH2 model was a seminal breakthrough in the field of 
immunology.  Further research into this delicate interplay has led to further delineation of 
inflammatory mediators; however, the use of the TH1 and TH2 archetype continues in use as a 
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way to gain insight about inflammation (Muller, 2002).  The notion of TH1 cells as strictly an 
anti-viral or anti-tumor reponse and TH2 as solely involved with humoral immune response has 
been redefined to examine many disease states.  T cell derived cytokines are being examined in 
disease states such as schizophrenia, depression, and chronic pain and cGVHD (Kim et al., 2004; 
Yoon, Kim, Lee, Kwon, & Kim, 2012).  Typically, IL-10 (produced by TH2 cells) acts to 
suppress secretion of IFN-y by TH1 cells and shifts immune response to cell-mediated immunity 
and dampens the immune response (Plotnikoff, Faith, Murgo, & Good, 2007). IL-6 inhibits TNF 
and IL-1β, thus associations noted in this study are consistent with the cytokine pathways 
(Kishimoto, 2010). Cytokine IL-6 has been identified as a key cytokine in symptoms of 
depression and fatigue and has been noted as a mediator of oral inflammation (Fall-Dickson, et 
al., 2010).  The positive association between lack of energy and IL-6 and the significant increase 
in serum levels, make IL-6 a candidate for a potential biomarker of fatigue in cGVHD.   
The NINR recognizes the negative impact symptoms have on quality of life and supports 
research to improve understanding symptoms and the biological mechanisms underlying 
symptoms (NINR, 2011).  The goal of which is to improve quality of life through better 
symptom management.  In studies of patients who received HSCT, patients without cGVHD one 
to two years following HSCT did not report having impaired QoL whereas patients with cGVHD 
reported QoL scores, at the same time-point following HSCT, below that of both population 
norms and other cancer patients (Baker & Frasier, 2008; Fall-Dickson et al., 2010; Webster, 
Cella, & Yost, 2003).  Some participants of this study had QoL scores that were below both 
general U.S. population and cancer population normative values.  Though this study reports QoL 
mean scores similar to U.S. population normative values, significant negative correlations were 
noted among symptoms and QoL.  Severity of cGVHD and symptoms have demonstrated a 
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negative correlation to QoL (Pidala et al., 2011; Pidala et al., 2012).  Findings of the significant 
negative correlations among symptoms and QoL suggest symptoms may be a predictor of QoL 
outcomes however, need to be examined further. 
There are some limitations of this study.  Genrealizability of these results is limited due 
to the small sample size of this study and lack of control group.  This study was conducted at a 
single site, limiting the number of participants eligible for this study.  The study was conducted 
at a center’s long term follow up clinic.  As such, patients are monitored closely for any 
complications consistently and may receive intervention earlier more frequently than individuals 
seen in other institutions performing bone marrow transplantation without a long term follow up 
clinic.  This may partially explain the low pain scores and/or higher mean QoL scores noted in 
this study.  There was no eligibility criteria set for the length of time since diagnosis although 
this was captured as an individual and disease factor.  This may have skewed important 
information about symptoms.  Time from onset of cGVHD may effect associations and should 
be considered as part of the eligibility criteria in future studies.  This study examined 
inflammatory markers, cytokines and CRP, but did not include the use of controls.  The result is 
a profile of levels of cytokines and CRP for this sample and does provide information useful in 
assessing these levels for future studies.  To compensate for the lack of a control group, 
inflammation was examined by symptom and individuals that did not have the symptom served 
as the control.  A confounder of this method may be the possibility of an inflammatory response 
preceding the behavioral response of the symptom.  This was a cross-sectional study thus a 
limitation is assessment of symptoms and biomarkers at a single time point.  Results may differ 
at another time. 
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The findings of this study provide a profile of the symptoms, inflammation and QoL of 
patients diagnosed with cGVHD and associations among those variables.  Noted were evidence 
of associations among symptoms and inflammation as were significant negative associations 
among symptoms and QoL.  Further examination of these associations should be tested using a 
larger sample with a longitudinal design to better understand the effect of time on these 
relationships and the impact of the symptom trajectory on QoL.  The presence of symptoms 
individuals with cGVHD experience emphasizes the significance for clinical evaluation of 
symptoms in this population and draws attention to existent relationships among symptoms, 
inflammation, and QoL. Further exploration of these relationships is pivotal in understanding the 
interplay among symptoms and inflammation and their impact on QoL and is essential towards 
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Full Time 10 41.2
Part Time 2 8.3




















Note: AML=acute myelogenous leukemia; CML= chronic myelogenous leukemia, MDS= myelodyplasic 
symdrome, MM= multiple myeloma; Diagnosis Other = non-Hodgkin’s lymphoma, B-cell lymphoma, T-
cell lymphoma, multiple myeloma; Conditioning Other = reduced intensity radiation and/or 






Disease Factors (N=24) 
Variable n %
cGVHD onset 
De Novo 17 70.8
Quiescent 4 16.7
Progressive 3 12.5




Number of organs involved 
1 4 16.7
2 8 33.3
>  3 12 50.0
Platelet  
< 100,000 4 16.7






Note: De Novo= never had acute chronic graft-versus-host disease (aGVHD); Quiescent= 
resolved aGVHD; Progressive= has signs of aGVHD but has progressed to cGVHD; platelet 














Frequency of Symptom Bother by Body System and Total Scores from the Lee cGVHD Symptom 
Scale (N=24) 
Symptom n (%) n (%) n (%) n (%) n (%) 










SKIN      
Abnormal skin color 12 (50.0) 3 (12.5) 4 (16.7) 3 (12.5) 2 (8.3) 
Rashes 14 (58.4) 6 (25.0) 2 (8.3) 2 (8.3) 0 
Thickened skin 20 (83.3) 0 1 (4.2) 0 3 (12.5) 
Sores on skin 18 (75.0) 4 (16.7) 2 (8.3) 0 0 
Itchy skin 13 (54.2) 2 (8.3) 5 (20.8) 3 (12.5) 1 (4.2) 
EYES AND MOUTH       
Dry eyes 4 (16.7) 3 (12.5) 5 (20.8) 7 (29.2) 5 (20.8) 
Need to use eye drops               
frequently 
5 (20.8) 1 (4.2) 3 (12.5) 5 (20.8) 10 (41.7) 
Difficulty seeing 
clearly 
7 (29.2) 3 (12.5) 7 (29.2) 3 (12.5) 4 (16.7) 
Need to avoid certain 
foods due to mouth 
pain 
17 (70.8) 4 (16.7) 0 1 (4.2) 2 (8.3) 
Ulcers in mouth 22 (91.7) 0 1 (4.2) 0 1 (4.2) 
Receiving nutrition 
from an intravenous 
line or feeding tube 
24 (100.0) 0 0 0 0 
BREATHING       
Frequent cough  14 (58.3) 1 (4.2) 4 (16.7) 4 (16.7) 1 (4.2) 
Colored sputum 18 (75.0) 3 (12.5) 2 (8.3) 0 1 (4.2) 
Shortness of breath 
with exercise  
6 (25.0) 6 (25.0) 4 (16.7) 5 (20.8) 3 (12.5) 
Shortness of breath at 
rest  
18 (75.0) 3 (12.5) 1 (4.2) 2 (8.3) 0 
Need to use oxygen  22 (91.7) 0 0 0 2 (8.3) 
EATING AND 
DIGESTION  
     
Difficulty swallowing 
solid foods 
16 (16.7) 5 (20.8) 2 (8.3) 0 1 (4.2) 
Difficulty swallowing 
liquids  
23 (95.8) 0 0 1 (4.2) 0 
Vomiting  21 (87.5) 1 (4.2) 2 (8.3) 0 0 
Weight loss 21 (87.5) 0 3 (12.5) 0 0 
MUSCLES AND JOINTS       




Symptom n (%) n (%) n (%) n (%) n (%)












13 (54.2) 4 (16.7) 3 (12.5) 3 (12.5) 1 (4.2)
Muscle cramps 12 (50.0) 6 (25.0) 2 (8.3) 1 (4.2) 3 (12.5)
ENERGY  
Loss of energy  5 (20.8) 6 (25.0) 7 (29.2) 4 (16.7) 2 (8.3)
Need to sleep 
more/take naps 
8 (33.3) 5 (20.8) 7 (29.2) 2 (8.3) 2 (8.3)




Depression 17 (70.8) 3 (12.5) 4 (16.7) 0 0
Anxiety 12 (50.0) 8 (33.3) 4 (16.7) 0 0




















Total Scores for the Lee cGVHD Symptom Scale and the Memorial Symptom Assessment Scale 
(MSAS) 
Variable Subscale Mean (SD) Median Range 
Lee cGVHD 
Symptom Scale 21.80 (13.00) - 4.1-45.5
Skin - 15.0 0.0-70.0
Eyes and Mouth 31.10 (20.20) - 0.0-83.3
Breathing - 17.5 0.0-65.0
Eating and Digestion - 6.3 0.0-43.8
Muscles and Joints - 21.9 0.0-93.8
Energy 25.70 (18.60) - 0.0-66.7
Mental and Emotional 20.80 (16.50) - 0.0-58.3
   
MSAS  00.65 (.43) - 0.2-1.7
 Global Distress Index 00.91 (.64) - 0.0-2.4
 Physical Symptoms 00.69 (.52) - 0.0-1.8
 Psychological Symptoms 00.74 (.54) - 0.0-2.0
Note: Scoring for the Lee cGVHD Symptoms Scale is 0-100 with higher scores indicating greater 















Table 5  












Difficulty Concentrating 13 2.25 (0.87) 1.42 (0.67) 1.42 (1.31) 1.69 (0.86)
Pain 12 2.92 (1.00) 2.6 (1.00) 2.08 (1.16) 2.70 (0.82)
Lack of Energy 20 2.84 (0.90) 2.16 (0.90) 2.11 (1.41) 2.37 (0.90)
Cough 14 2.29 (0.91) 1.64 (0.63) 1.41 (1.23) 1.69 (0.78)
Feeling Nervous 8 1.88 (0.35) 1.14 (0.38) 0.86 (0.38) 1.29 (0.23)
Dry Mouth 16 3.50 (0.63) 2.31 (0.95) 2.06 (1.24) 2.63 (0.78)
Nausea 4 1.50 (0.58) 1.75 (0.50) 1.50 (1.00) 1.58 (0.57)
Feeling Drowsy 14 2.07 (0.62) 1.64 (0.63) 1.00 (0.88) 1.57 (0.48)
Numbness/Tingling in Hands and 
Feet 13 2.54 (1.05) 1.31 (0.48) 1.08 (0.95) 1.64 (0.66)
Difficulty Sleeping 12 2.76 (0.93) 2.00 (0.91) 1.46 (1.20) 2.06 (0.87)
Feeling Bloated 5 3.40 (0.55) 2.20 (1.10) 2.80 (1.10) 2.80 (0.84)
Problems with Urination 4 2.50 (0.58) 1.25 (0.50) 2.25 (1.50) 2.00 (0.61)
Vomiting 2 2.00 (0.00) 2.00 (1.41) 2.50 (2.12) 2.17 (1.18)
Shortness of Breath 13 2.53 (1.00) 1.92 (0.86) 1.85 (1.34) 2.10 (0.99)
Diarrhea 2 2.50 (0.71) 1.50 (0.71) 1.50 (0.71) 1.83 (0.71)
Feeling Sad 6 1.83 (0.41) 1.33 (0.52) 1.50 (0.55) 1.56 (0.34)
Sweats 6 2.67 (0.52) 1.67 (0.52) 1.83 (1.67) 2.06 (0.71)
Worrying 14 1.79 (0.58) 1.36 (0.50) 1.00 (0.56) 1.38 (0.45)
Sexual Dysfunction 11 2.73 (1.10) 2.55 (1.29) 2.82 (1.25) 2.47 (1.31)
Itching 8 2.38 (0.92) 1.50 (0.76) 1.38 (1.19) 1.75 (0.89)
Lack of Appetite 2 3.50 (0.71) 3.00 (1.41) 3.00 (1.41) 3.17 (1.18)
Dizziness 2 2.00 (0.00) 1.50 (0.71) 1.50 (0.71) 1.67 (0.47)
Difficulty Swallowing 7 2.14 (0.69) 1.86 (0.69) 2.14 (1.57) 2.05 (0.91)
Feeling Irritable 8 1.63 (0.74) 1.25 (0.46) 1.50 (1.41) 1.46 (0.69)
Mouth Sores* 3 N/A 1.33 (0.58) 1.33 (1.53) 1.33 (1.04)
Change in Taste* 3 N/A 1.00 (0.00) 2.00 (0.00) 1.50 (0.00)
Weight Loss* 2 N/A 1.50 (0.71) 1.50 (2.12) 1.50 (1.40)
Hair Loss* 5 N/A 2.40 (1.52) 2.00 (1.58) 2.20 (0.91)
Constipation* 3 N/A 3.00 (1.73) 2.33 (2.08) 2.67 (1.89)
Swelling Arms/Legs* 7 N/A 2.00 (0.58) 2.00 (1.50) 2.00 (0.71)
Don't Look Like Myself* 7 N/A 2.14 (1.07) 2.57 (.98) 2.36 (0.99)
Skin Changes* 8 N/A 2.25 (1.04) 2.34 (1.06) 2.31 (1.00)
Note: *Only severity and distress are measured for these symptoms; SD=standard deviation; scores are 




Mean Scores of Cluster Symptoms 
Measure Mean (SD) Median Range
Brief Pain Inventory  
Total - 0.3 0-6.4
Interference - 0.0 0-8.3
Severity - 0.8 0-5.8
Hospital Anxiety and Depression Subscale 4.1 (3.5) - 0-11.0
Brief Fatigue Inventory  
Total 3.0 (2.4) - 0-8.0
Interference 2.4 (2.6) - 0-9.5






















Cytokine and C-reactive Protein (CRP) Distributions 
Inflammatory 
Marker 
Mean (SD) Median Range
Cytokines    
IL-1β 4.70(4.31) 0.03-14.93
IL-6 23.70 (20.20) 0.01-85.50
IL-10 - 16.00 0.50-109.08
TNF 27.05(25.17) 1.27-96.16
IFNy 126.56 (124.30) 2.03-508.17
CRP - 6.42 0.53-90.00
Note: Cytokines are reported in picograms/milliliter; CRP=C-reactive protein; CRP is reported 




















Quality of Life Scores from the FACT-BMT 
Measure Subscale Mean (SD) Range
FACT_BMT (0-148) 113.28 (20.90) 58-136
 FACT_G (0-108) 83.89 (16.15) 41-101
 BMTS (0-40) 29.38 (5.44) 17-38
 TOI (0-96) 69.08 (16.76) 30-88
PWB (0-28) 20.66 (6.59) 6 to 27
SWB (0-28) 23.99 (3.68) 12 to 28
EWB (0-24) 20.21 (3.18) 10 to 24
FWB (0-28) 19.04 (6.16) 5 to 28
Note: FACT= Functional Assessment of Cancer Therapy; G= General; BMT=Bone Marrow 
Transplant; S= subscale; PWB= Physical Well-being; SWB= Social Well-being; EWB= 
Emotional Well-being; FWB= Functional Well-being; TOI= Trial Outcome Index and is the sum 











































 1 2 3 4 
1-BPI 1.00 0.36 0.24 -0.51 
2-HADS-D 0.36 1.00 0.82 -0.87 
3-BFI 0.24 0.82 1.00 -0.80 
4-FACT-BMT -0.51 -0.87 -0.80 1.00 
Note: A p value < .05 was considered statistically significant.  Pain significantly correlated 
with quality of life; depression significantly correlated with fatigue and quality of life; fatigue 
significantly correlated with quality of life; BPI= Brief Pain Inventory; HADS-D= Hospital 
Anxiety and Depression subscale; BFI= Brief Fatigue Inventory; FACT-BMT= Functional 















Figure1. Biobehavioral Conceptual Model to Examine Chronic Graft-Versus-Host-Disease.  
Chronic graft-versus-host disease (cGVHD) is influenced by individual and disease factors and 
influences symptoms. There is an interaction between cGVHD and inflammation. Inflammation 





























































Figure 2. Correlations found in this study between the Brief Pain Inventory (BPI) total measure (T) and the 
subscales interference (I) and severity (S) and the Brief Fatigue Inventory (BFI) total measure (T) and the subscales 























Figure 3. Correlations found in this study between the Hospital Anxiety and Depression Scale (HADS) depression 
subscale (D) and the Brief Pain Inventory (BPI) total measure (T) and the subscales interference (I) and severity 
(S). Correlations found in this study between the HADS-D and the Brief Fatigue Inventory (BFI) total measure (T) 
and the subscale interference (I) and severity (S). A p value less than .05 is considered significant. The symbol (*) 
marks significant correlations.   
HADS_D 
HADS D 















































































































































































































































     
   




































































































































































   
   
   
   
   
   
   
 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

































































































































































































































































































































































































































































































































































































To better understand the symptomology of chronic graft-versus-host disease (cGVHD) 
inclusive of possible biological mechanisms of symptoms and how they may relate to quality of 
life (QoL), this dissertation study focused on elucidating a profile of symptoms, inflammation, 
and QoL in a sample of participants diagnosed with cGVHD.  In addition, it was of interest to 
determine if there were relationships between and among these variables.  As a certified 
oncology nurse working with bone marrow transplant recipients, this researcher witnessed the 
distress caused by cGVDH.  Symptoms were particularly distressing for patients and were often 
difficult to manage, yet there was not much known about typical symptoms or if certain 
symptoms co-occurred.  Secondly, as cGVHD is a complication individuals are living with, at 
times for many years, survivorship issues, such as QoL, are of interest in cGVHD research and 
have been suggested to be included in clinical trials as possible endpoints to determine 
intervention efficacy (Filipovich et al., 2005; Schulman, 2006). 
 Cytokines, a surrogate marker of inflammation, have been found to be associated with 
symptoms of cancer such as pain, depression and fatigue (Meyers, 2008; Seruga, 2008). 
Cytokines have also been examined in cGVHD and have been found to be associated with some 
auto-immune diseases that present similarly to cGVHD (Baird & Montaine, 2008; Klimiuk, 
Sierakowski, Domyslawska, & Chwiecko, 2011). Therefore, it was a logical for this researcher to 
explore cytokines previously examined in cGVHD, in symptoms individuals with cGVHD may 
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be experiencing.  Of specific interest to this researcher was knowing which symptoms present 
with cGVHD and to what extent, through a biobehavioral lens, and how QoL is affected by 
cGVHD.  The first step in this research inquiry was a review of the literature to determine what 
was already known and where there were gaps that needed to be addressed.  Findings from this 
empirical review prompted the specific aims for this initial research into the symptomology of 
cGVHD.  
 Using the knowledge about the gaps in literature into the symptomology of cGVHD, a 
study was proposed to describe the symptoms, inflammation, and QoL in individuals diagnosed 
with cGVHD and examine the associations between and among symptoms (cGVHD specific, 
general [prevalent in other cancer populations], and cluster [pain, depression, and fatigue]), 
inflammatory markers (IL-1β, IL-6, IL-10, TNF and IFN-γ) and CRP, and QoL.  To this 
researcher’s knowledge, this is the first study using the general symptom measure (MSAS) and 
cluster symptom measures (BPI, HADS, and BFI) in this population.  
 There were several prominent symptoms noted across all symptom measures. 
Comparisons of pro-inflammatory cytokines and CRP levels were noted to show an observed 
pattern of elevation in individuals reporting the presence of specific general symptoms as 
opposed to individuals who did not report having the same symptom. Cytokine IL-6 had a 
significant increase between individuals reporting lack of energy and individuals without lack of 
energy.  Pain, depressive symptoms, and fatigue were noted in many participants. There did not 
seem to be any decrease in QoL means for the FACT-BMT total; however, the PWB and the 
FWB subscales demonstrated the lowest scores. Several individuals had lower than average QoL 
scores.  There were significant correlations between and among symptoms, inflammatory 
markers, and QoL. Significant correlations among domains of pain, depression and fatigue, 
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indicate the possibility of a symptom cluster.  Inflammatory markers were consistent with 
cytokine pathways and appear to be over-expressed in this sample of individuals. There were 
many negative associations among symptoms and QoL indicating a possibility of symptom 
influence on QoL. This study provides preliminary information into the interplay between 
inflammation and symptom presentation and need to be examined further to make any 
conclusion.  The initial plans for this program of research will be to replicate this study with the 
following: 1) a larger sample size, 2) use of a control group for cytokine comparison, and 3) use 
of in-depth measures of noted general symptoms such as sleeping difficulty.   
One of the most significant findings in this study was the presence of symptoms that may 
be only suspect of a particular site of cGVHD such as dry mouth or sexual dysfunction.  
Thorough assessment of symptoms is necessary to most effectively manage symptoms. Evidence 
about how symptoms present and the frequency and severity of symptoms, provides information 
for use when assessing patients’ symptoms. 
Another key finding of this study was the potential influence inflammation may have on 
symptom presentation.  Knowledge about symptoms and mechanisms affecting the frequency 
and severity of symptoms may enable practitioners to implement strategies for anticipatory 
guidance of cGVHD complications during pre and post transplant counseling. 
Significant differences in cytokine levels Il-1β, Il-6, and IL-10 make these cytokines 
candidate markers for future investigation.  The complication of cGVHD is complex and the 
etiology is poorly understood.  Current research is focused on identification of target biomarkers 
for identification of possible disease initiation, progression, remission, and recurrence. It is of 
interest to know how cGVHD manifests.  Knowing if symptoms and cytokines cluster by body 
system and if cGVHD clusters by body system is of interest.  There may be different biological 
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and behavioral profiles depending on the affected site.  Knowledge about how symptoms present 
and biological mechanisms, such as inflammation, is fundamental to the development and testing 
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Search Terms for State of the Science Manuscript 
 
 
The PubMed search terms to capture literature about symptoms and cGVHD were 
(("Signs and Symptoms"[Mesh] OR Symptom*[Title/Abstract])) AND (("Graft vs Host 
Disease"[Majr] OR Chronic Graft-vs-Host Disease* OR Chronic Graft versus Host 
Disease*[Title/Abstract] OR cGVHD[Title/Abstract] NOT Acute Graft-vs-Host 
Disease*[Title/Abstract] OR Acute Graft versus Host Disease*[Title/Abstract] OR 
aGVHD[Title/Abstract] AND (English[lang])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH])).  The PubMed search terms to capture 
literature about cytokines and cGVHD were (("Cytokines"[Mesh] OR cytokines[Title/Abstract] 
AND ("last 10 years"[PDat] AND Humans[Mesh] AND English[lang] AND adult[MeSH]))) 
AND (("Graft vs Host Disease"[Majr] OR Chronic Graft-vs-Host Disease* OR Chronic Graft 
versus Host Disease*[Title/Abstract] OR cGVHD[Title/Abstract] NOT Acute Graft-vs-Host 
Disease*[Title/Abstract] OR Acute Graft versus Host Disease*[Title/Abstract] OR 
aGVHD[Title/Abstract] AND (English[lang])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH]).  The PubMed search terms to capture 
literature about quality of life and cGVHD were (("Cytokines"[Mesh] OR 
cytokines[Title/Abstract] AND ("last 10 years"[PDat] AND Humans[Mesh] AND English[lang] 
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AND adult[MeSH]))) AND (("Graft vs Host Disease"[Majr] OR Chronic Graft-vs-Host Disease* 
OR Chronic Graft versus Host Disease*[Title/Abstract] OR cGVHD[Title/Abstract] NOT Acute 
Graft-vs-Host Disease*[Title/Abstract] OR Acute Graft versus Host Disease*[Title/Abstract] OR 
aGVHD[Title/Abstract] AND (English[lang])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH])) AND ("last 10 years"[PDat] AND 
Humans[Mesh] AND English[lang] AND adult[MeSH]).  The CINAHL search terms to capture 
literature about symptoms and cGVHD were ((MH "Graft Versus Host Disease") OR Chronic 
Graft-vs-Host Disease* OR Chronic Graft versus Host Disease* OR cGVHD) NOT (Acute 
Graft-vs-Host Disease* OR Acute Graft versus Host Disease* OR aGVH) AND ( (MH "Signs 
and Symptoms (Non-Cinahl)") OR (MH "Symptoms") OR symptom* ).   
The CINAHL search terms to capture literature about cytokines and cGVHD were ((MH 
"Graft Versus Host Disease") OR Chronic Graft-vs-Host Disease* OR Chronic Graft versus Host 
Disease* OR cGVHD) NOT (Acute Graft-vs-Host Disease* OR Acute Graft versus Host 
Disease* OR aGVH ) AND ((MH "Cytokines OR Chemokines (Non-Cinahl)") OR (MH 
"Cytokines OR Chemokines") OR cytokine OR chemokine* ).  The CINAHL search terms to 
capture literature about quality of life and cGVHD were ((MH "Graft Versus Host Disease") OR 
Chronic Graft-vs-Host Disease* OR Chronic Graft versus Host Disease* OR cGVHD) NOT 
(Acute Graft-vs-Host Disease* OR Acute Graft versus Host Disease* OR aGVH ) AND ( (MH 





 Chronic Graft Versus Host Disease 
Enrollment Documentation 
Study ID: ___ ___ ___ ___ 
Date of Enrollment: ____________________________ 
Please check all that apply: 
_____The patient is at least 21 years of age 
_____The patient has a diagnosis of cGVHD 
_____The patient is able to understand and speak English  
_____The patient does not have dementia 
_____The patient does not have active psychosis 
_____The patient has not started any anti-depressant medication within 30 days 
_____The patient is not pregnant 
_____The patient is not incarcerated  
If any of the above is not verified, the patient should NOT be enrolled in the study. 
The following has been discussed with the patient: 
_____The informed consent in its entirety 
_____The voluntary nature of the study 
_____Alternatives to participation 
_____Questions about the study 
The following actions have been completed: 
_____The patient has willingly agreed to participate in the study 
_____The patient has verbalized understanding of the study and has signed the consent form 
_____The patient has received a copy of the signed consent form 




A trained staff member will meet the patient at scheduled visit to complete study session. 




Study Nurse: ______________________________________ Date: ___________________________ 














Verified by:   _______________________________  Date: ____________ 
 
Sent to Data Entry Date: _____________________  Received from Data Entry Date: _______________ 
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Study ID ______________________________ 
Date  ______________________________ 
Data Collected by (Please Print): _______________________________________ 































_______ Demographic with 
Disease Profile 
________ MSAS 
________ Lee Symptom Bother 
Data Collected 
_______ Patient received Gift Card    ___________________________ Gift Card Number 
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